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1. Theoretical introduction and review of literature 
 
                                                  1.1. INTRODUCTION 
 
A core principle of current medicine is the „biopsychosocial“ model of human illness 
that implicates close connection among various ethiological factors in disease 
initiation and progession (Engel, 1977). Coexistence of those factors historically 
initiated the term „psychosomatic illness“, which denotes that medical disorders may 
be signicantly influenced by psychological factors (Levenson and James, 2006). 
Further development of this concept within the framework of psychosomatic 
medicine emphasized physiological interactions between psychological states, 
emotions, autonomic, neuroendocrine and immunological response and implicated its 
broader implications in biological sciences and medicine. Attempts to explain basic 
psychological characterists and pathophysiological processes in psychosomatic 
patiens generated several theories that have emerged in the recent decades. 
Hypothesis that aversive emotional states are associated with adverse health 
outcomes (Kiecolt-Glaser et al., 2002) and that interference with the experience or 
expression of emotions, particulary negative, can have negative affect on health 
belong among most important principles (Levenson, 1994; Lane, 2008). In this context, 
physiology of emotions represents important area in the field of psychosomatic 
research.  Consecutive research has confirmed this assumption in numerous studies 
and emhasized evidence that dysregulation of an emotional experience and its 
expression has negative effects on health of the individual (Taylor, 1987; Kiecolt-
Glaser et al., 2002; Guilbaud et al., 2003).  Already Alexander (1943, 1950) has 
proposed that some specific changes of mental functions and typical alterations in 
cognitive and affective functioning may cause psychosomatic diseases. Alexander 
suggested that not only onset, but also a course of many somatic illnesses are 
influenced by repression of certain conflicting ideas and related emotional 
disturbances.  Conceptualisation of psychosomatic disorders by Ruesch in 1948 has 
pressumed that a deficit or developmental arrest in the capacity of symbolic mental 
representations of emotions is a basic dysfunction in psychosomatic patients. Further 
research in this direction has led to development of a model connecting the 
psychosomatic diseases with functions of the „visceral brain“ (MacLean, 1949). This 
model suggested that when emotional feelings do not find expression and discharge 
in the symbolic use of words and behaviour, emotions may be „transformed“ into 
somatic states as an„organ language“. French psychoanalytic researchers Marty and 
M’Uzan (1963), coined the term „pensée opératoire“  which means, “operativ 
thinking“ and decribes characteristic signs of psychosomatic pacients mainly 
characterized as behavior without emotions as a consequence of stress-induced 
internal psychic arousal (Nemiah, 2000).   
Nemiah and Sifneos in 1970s have observed that many patients with the so-called 
“psychosomatic” diseases have deficits in capacity of symbolization of emotions, 





psychotherapy. The authors have proposed that these features can cause various  
symptoms including physiological dysfunctions  that may result in various illnesses, 
dispositions to impulsive behavior, discomfort or avoidance of social relationships 
and decreased capacity for self-care and self- regulation. This hypothesis has 
afterwards evolved into the concept of alexithymia proposed by Sifneos in 1973. 
Alexithymia concept today represents one of the key concepts in psychosomatic 
medicine that links the influence of emotions and personality types and/or features on 
physical illnesses and health. Sifneos (1994, 1996) used the term  „alexithymia“ in 
order to describe one of the basic traits of psychosomatic patients that is characterised 
by diminution or absence of the ability to experience feelings which is one of the most 
strikikng human characteristics. From the beginning of the alexithymia research it was 
hypothesized that alexithymic features of the personality can influence and even 
contribute to the development or maintanence of psychosomatic illness (Bach and 
Bach, 1995; Ahlberg et al., 2004). Some authors also emphasized focus on alexithymia 
research in order to find appropriate procedures for treatment of psychosomatic 
patients. Further research has confirmed the hypothesis suggesting significant 
association between alexithymia and psychosomatic complaints (Sifneos 1973, 1975; 
Krystal 1979; Cooper and Holstrom, 1984).  
Worthy of mentioning is also the fact that alexithymia concept has continuosly 
underwent its development. Originally alexithymia concept has evolved from the 
field of psychoanalysis, but consequently the wider scientific arena has taken an 
interest in alexithymia research (Bagby and Taylor, 1997; Lane et al., 1997, De Gucht 
and Heiser, 2003). Although the alexithymia concept origins in the area of 
psychosomatics (Nemiah and Sifneos, 1970; Sifneos, 1973), later focus on alexithymia 
significantly extended on general aspects of emotional influences on mental and 
somatic health (Taylor et al., 1991). Following this progress alexithymia developed 
into clinically relevant concept confirmed by a large body of empirical data (Taylor et 
al., 1997; Taylor, 2000, Taylor and Bagby, 2004) and currently the Pubmed database 




1.2. DEFINITION OF ALEXITHYMIA CONCEPT 
 
Since the 1970s many researches have contributed to the development of alexithymic 
concept (Taylor et al., 1991, 1997). Today alexithymia represents multidimensional 
construct that generally reflects deficits in the cognitive processing and the regulation 
of emotions, which remain undifferentiated, poorly regulated and disrupted from 
conscious experience (Lane et al., 1996, 1997; Taylor et al., 1991; Larsen et al., 2003; 
Taylor and Bagby, 2004; Bermond et al., 2006). Some authors conceptualized 
alexithymia as a deficit in both cognitive and affective aspects of the mental emotional 
responses (Vorst and Bermond, 2001) and found that alexithymic features are 





alexithymia was coined by Sifneos in 1973 and in exact translation means „ no words 
for feelings “; „absence of words for emotions“, or „without words for emotions“.  The 
Greek designation alexithymia is based on a few Greek words as follows: a = lack, 
lexis = word, thymos = emotion. The core features of alexithymia include a set of four 
basic cognitive-affective deficits characterised by a deficit in experience and 
identifying of various feelings, deficits in introspective ability to describe feelings, 
decreased fantasy and externaly oriented cognitive style (Nemiah and Sifneos, 1970; 
Sifneos, 1972; Nemiah et al., 1976; Taylor, 2000).  
 
Typical characteristics of alexithymic persons are: 
1. They report less emotional experiences and deficit in reaching the conscious 
awareness of emotions. Alexithymia also involves a marked deficit in identifying  
one‘s own emotional states, deficit in distinguishing between various feelings and 
little insight into his/her own feelings and psychosocial processes (Sifneos 1973; 
Nemiah et al., 1976). In addition, there is difficulty in distinguishing between 
emotions and verbally communicating feelings (Nemiah and Sifneos, 1970; Sifneos, 
1972; Nemiah et al., 1976; Taylor, 2000). Some authors have proposed that alexithymic 
persons might be emotionally aroused just as much as non-alexithymic ones, however, 
they would report they do not feel anything or do not know how they feel, and 
consequently can not regulate their emotional states (Lane et al., 1997). Such 
impairment could lead to a relative inability to use one‘s own emotions to guide 
adaptive behaviour (Ogrodniczuk et al., 2011). Alexithymia is also characterised by 
difficulty in differentiating emotions from physiological states and a tendency to 
somatization (De Gucht and Heiser, 2003; Taylor and Bagby, 2004). In this context it 
has been observed association between alexithymia and an impaired capacity for 
emphaty (Guttman and Laporte, 2002). This relationship might be explained with the 
model of “shared network” suggesting that the networks responsible for processing of 
emotions in the self are the same networks used to represent the emotions of others 
(Singer et al., 2004, 2006; Bird et al, 2010). 
2. Alexithymic persons are also characterized by deficits in describing and expressing 
one‘s own emotional states with propensity to offering undifferentiated descriptions 
of emotional experiences. Another typical feature is defined by limited capacity to 
elaborate upon emotional experience and a limited capacity to symbolize emotions 
(Nemiah and Sifneos, 1970; Sifneos, 1972; Nemiah et al., 1976, Taylor, 2000). 
Alexithymic subjects occasionally describe emotional experiences, however that is 
stereotyped and at time wooden. This observation could be explained by findings, 
that exteroceptive pathway processing emotional information could be intact, 
suggesting that in some situations alexithymic individuals describe emotions that they 
think they should feel based on exteroreceptive cues, but do not consciously 
experience them (Lane et al., 1997). In this context it has been proposed that 
alexithymic individuals are like colorblind subjects, who learn to associate certain 
color words with objects, e.g. , green for grass, even though they do not experience the 





3. Alexithymic persons have paucity of fantasies, impoverished fantasy life and 
limited imagination abilities (Sifneos, 1973; Warnes, 1986; Taylor, 2000).  
4.  It can be also observed an externaly oriented cognitive style that engages in 
externally oriented rather than psychologically minded thought (Sifneos, 1973; 
Nemiah et al. 1976).  
 
There are also some other psychological features that are commonly associated with 
alexithymia.  For example, alexithymic subjects sometimes manifest propensity to 
impulsive behaviour (Warnes, 1986; Taylor, 2000) and flattened emotions 
accompanied by random and abrupt emotional outbursts which they cannot interpret 
(Nemiah and Sifneos, 1970). Alexithymia could be also associated with a deficit in 
maintaining the voluntary control of emotions, overcontrol of their internal needs, 
exagaggerated defensive system (Gu et al., 2008) and personality dimensions as 
introversion, neuroticism, and low openness (Bagby et al., 1994b). 
In agreement with other authors (Taylor et al., 1985; Hendryx et al., 1991), Bermond et 
al. (1999, 2006) defines alexithymia as an inability to complete emotional experience, 
which means, that the person is not able to experience feelings, differentiate between 






























 Table 1a. The most and least characteristic features of alexithymia according to the    
 California  Q-set (CAQ) (adapted from Haviland and Reise, 1996). 
……………………………………………………………………………………………………. 
Extremely                     1. Is emotionally bland; has flattened affect. 
characteristic                2. Anxiety and tension find outlet in bodily symptoms. 
                                       3. Is concerned with own body and the adequacy of its   
                                           physiological functioning. 
                                       4. Emphasizes communication through action and nonverbal  
                                           behaviour. 
                                       5. Keeps people at a distance; avoids close interpersonal  
                                           relationships. 
…………………………………………………………………………………………………… 
Quite                              1. Has a brittle ego-defense system; has a small reserve of  
Characteristic                   integration; would be disorganized and maladaptive when  
                                           under stress  or trauma. 
                                       2. Judges self and others in conventional terms like  
                                            “popularity,” “the correct thing to do,” social pressures, etc. 
                                       3. Is uncomfortable with uncertainty and complexities. 
                                       4. Handles anxiety and conflicts by, in effect, refusing to  
                                           recognize their presence; repressive or dissociative               
                                           tendencies. 
                                       5. Tends toward overcontrol of needs and impulses; binds  
                                           tensions excessively; delays gratification unnecessarily. 
…………………………………………………………………………………………………… 
Extremely                      1. Engages in personal fantasy and daydreams, fictional  
Uncharacteristic                 speculations. 
                                        2. Has insight into own motives and behavior. 
                                        3. Has warmth; has the capacity for close relationships;  
                                            compassionate. 
                                        4. Is introspective and concerned with self as an object. 
                                        5. Enjoys esthetic impressions; is esthetically reactive. 
…………………………………………………………………………………………………… 
Quite                             1. Is skilled in social techniques of imaginative play,  
Uncharacteristic              pretending, and humor. 
                                       2. Is socially perceptive of a wide range of interpersonal cues 
                                       3. Responds to humor. 
                                       4. Initiates humor. 
                                       5. Is concerned with philosophical problems; e.g., religions,  
                                           values, the meaning of life, etc. 
                                       6. Enjoys sensuous experiences (including touch, taste, smell,   
                                          physical contact). 






1.3. STABILITY OF ALEXITHYMIA 
 
A core issue of alexithymic manifestations is a level of their stability during individual 
life (Sifneos, 1973; Taylor and Bagby, 2004; Luminet et al. 2007). In this context, 
alexithymia as a stable personality trait has been demonstrated in several longitudinal 
studies in variuos populations (Schmidt et al., 1993; Salminen et al., 1994; Wise et al., 
1995, Porcelli et al., 1996; Luminet et al., 2007; Tolmunen et al., 2011). On the other 
hand several research data has shown that alexithymia could also present a state-like 
secondary phenomenon (Freyberger, 1977) and some findings suggest that 
alexithymia could represent consequence of psychological distress and a response to 
cope with distress of depressive symptoms like emotional pain, aversive memories 
and psychological arousal (Freyberger, 1977). These data have led to distinguishing 
specific forms of alexithymia and definition of primary secondary alexithymia. 
Primary alexithymia is defined as a disposition factor, and stable long-term trait 
developed very early in life and possibly genetically and neurologically based. On the 
other hand secondary alexithymia is defined as state-like phenomenon related to 
protective and defence mechanisms, frequently developed to psychological trauma or 
response on serious somatic illness and  comorbid conditions (Freyberger, 1977; Wise 
et al., 1990a, 1990b; Horton et al., 1992; Fukunishi et al., 1997a, 1997b; Honkalampi et 
al., 2001a, 2001b; Saarijarvi et al., 2000, 2006; Joukamaa et al., 2003; Taylor and Bagby, 
2004; Marchesi et al., 2008; Tolmunen et al., 2011). In principle, these data are in 
agreement with findings reported by cross-sectional and follow-up studies that 
examined levels of stability in alexithymia (Salminen et al., 2006; Marchesi et al., 2008; 
Tolmunen et al., 2011) and found  absolute, as well as relative stability of alexithymia 
(Tolmunen et al., 2011). The absolute stability of alexithymia is present when the TAS 
scores of a subject remain the same during lifetime and is less dependent or 
independent on actual life events (De Timary et al., 2008a). For example, absolute 
stability of alexithymia has been observed in the study performed on 755 subjects 
(from general Finish population) which shown that 63.8% of the subject remained 
alexithymic after 11-year follow up (Tolmunen et al., 2011). Similarly, Tolmunen et al. 
(2011) found that correlations of alexithymia and its subscales between baseline and 
follow-up scores are significantly high (p = 0.51-0.63). 
Together these findings suggest that relative stability of alexithymia occurs when 
positive and highly significant correlations between total alexithymia scores and its 
subscales in several follow-up periods are present (Santor et al., 1997; Mikolajczak and 
Luminet, 2006; De Timary et al., 2008a).  
Based on these findings alexithymia likely is a personality trait as well as a state-
dependent phenomenon. A balance between the trait and state components of 
alexithymia vary among people and situations (Lumley et al., 2007) or it may be 
understood as a personality trait consisted of both trait and state components 
(Tolmunen et al, 2011) which may explain its relative stability (Taylor and Bagby, 
2004; Marchesi et al., 2008). In this context, the issue of alexithymia stability during the 





level of stressful life events that influence mental instability due to a need to use 
various forms of adaptive or maladaptive behavior that may significantly change 
personality profile related to mental and behavioral patterns.  
 
 
                                          
                                                 1.4. TYPES OF ALEXITHYMIA 
 
Main historical description of alexithymia types provided Freyberger (1977) in his 
concept of primary and secondary alexithymia but also other authors such as 
Bermond (Bermond et al., 2006)  and Chen (Chen et al., 2011) described different 
subtypes of alexithymia based on a distribution of various alexithymic features and its 
association with occurrence of different behavioural manifestations. 
 
Freyberger´s primary and secondary alexithymia:  
Freyberger (1977) has distinguished alexithymia in patients with somatic disorders 
into two subtypes and defined the terms: primary and secondary alexithymia. 
Primary alexithymia was defined as a disposition factor, representing a stable long-
term trait developed early in life and possibly genetically or neurologically based. On 
the other hand secondary alexithymia was defined as state-like secondary 
phenomenon related to protective and defence mechanisms as a response to 
psychological trauma or serious somatic illness. 
  
Bermond´s three subtypes of alexithymia: 
Bermond and coworkers (2006) based upon phenomenological analyses have 
proposed three subtypes of alexithymia.  
Type-1: is characterized by an absence or low level of conscious awareness related to 
emotional arousal and the emotion accompanying cognitions. 
Type-2: is characterized by higher degree of emotional experience but an absence of 
the normally accompanying cognitions. 
Type-3: is characterized by low affective and high cognitive processing of emotions 
capacities. 
Subjects with normal affective and cognitive processing of emotions were asigned as 
lexithymic.  
It has also been suggested that the alexithymia of the Type-1, may be predominantly 
biologically determined, while alexithymia of the Type-2, may be trauma-related 
(Bermond et al., 2006). The author has also suggested that each of these alexithymic 
subtypes might be related to the different neuronal or functional deficit (Bermond et 
al., 2006).  
 
Chen´s three subtypes of alexithymia: 
Chen and collegues (2011) focused their research on assessment of emotional 





They described subtypes of alexithymia in a sample of 1788 healthy students and 
found that alexithymia scores are differentielly associated with emotional regulation 
suggesting three subtypes of alexithymia which may be characterised by different 
behavioural manifestations. They proposed three distinct units related to typology 
conditions: 
1. Extrovert-high alexithymia (EHA) characterized by high score on Externally 
Oriented Thinking (EOT) subscale of the TAS (Toronto Alexithymia Scale) but normal 
score on the other alexithymic subscales.  
2. General-high alexithymia (GHA) characterized by general high scores on all three 
factors. This type of alexithymia is similar to the type-I of the Bermond´ classification.  
3. Introvert-high alexithymia (IHA) characterized by high scores on Difficulty 
Identifying Feelings (DIF) subscale and Difficulty Describing Feelings (DDF) subscale, 
but low score on EOT subscale of the TAS. 
The GHA and IHA are defined by suppressive character of emotional regulation and 
expression with worse emotion status as compared to the EHA and NA. GHA and 
IHA are marked by poorer emotional regulation and expression with worse emotional 
status. EHA seems to be modest in emotional status, with better emotion regulating as 
compared to the GHA (Chen et al., 2011). These findings suggest that several subtypes 
of alexithymia with different emotional expression and regulation abilities could be 




1.5 EPIDEMIOLOGY OF ALEXITHYMIA 
 
The prevalence of alexithymia is most frequently described as a percentage of the 
subjects in population reaching total score of Toronto Alexithymia Scale (TAS) ≥74 
(TAS-26) (Taylor and Bagby, 1988) respectively ≥61 (TAS-20) (Bagby et al., 1994a). 
With respect to this definition the prevalence of alexithymia in the large adult 
comunity samples was repeatedly amounted to be around 10-20% (Salminen et al., 
1999; Honkalampi et al., 2000a; Quinton and Wagner, 2005; Moriguchi et al., 2007). On 
the other hand the prevalence of alexithymia in clinical samples with some mental 
health and somatic disorders were significantly higher, amounted to be between 13,8 
% (Prochnow et al., 2011) and 77%  (Eizaguirre et al., 2004; Parling et al., 2010). 
The gender differences in alexithymia epidemiology were not confirmed (Joukamaa et 
al., 1996; Moriguchi et al., 2007) and the results were variable (Kokkonen et al., 2001; 
Parker et al., 2003; Franz et al., 2008). Therefore today it is not possible to conclude if 
any gender associated differences in alexithymia are present or not. Several studies 
also have shown positive association between alexithymia and age (Salminen et al., 
1999; Honkalampi et al., 2000b, Parker et al., 2003; Onor et al., 2010). Some authors 
tend to explain this observation by age-related poorer neurocognitive abilities (Onor 
et al., 2010) but there are also several studies that have found conversely negative 





2007). In addition alexithymia has been found associated with some epidemiological 
data, for example living alone or broken family (Kokkonen et al., 2001; Franz et al., 
2008), lack of relationships and close friends (Mattila et al., 2010a), lower educational 
level, life dissatisfaction (Mattila et al., 2007) and poorer socio-economic situation 
(Honkalampi et al., 2000b; Kokkonen et al., 2001; Parker et al., 2003; Franz et al., 2008).  
Worthy of the mentioning is also that several shortcomings of the alexithymic 
epidemiological studies could be responsible for the equivocal results of some studies. 
Firstly, use of different alexithymia measures may be partialy responsible for this 
variability. Moreover the majority of the population studies were performed mostly in 
countries as Finland, Germany, Japan, USA and Italy.  This in fact could also influence 
previous results, because alexithymia scores may vary across different ethnic groups, 
populations and language versions (Dion, 1996; Kooiman et al., 2002; Le et al., 2002; 
Müller et al., 2003; Lumley et al., 2005). It was assumed that these intercultural 
differences could be results of the differences in the cultural value of attending to and 
expressing feelings and differences in socioeconomic factors such as education and 
income (Dion, 1996; Salminen et al., 1999; Lumley et al., 2005). 
 
                                                                    
 
1.6. MEASUREMENT OF ALEXITHYMIA 
 
Symptoms of alexithymia are generally distributed in the population (Bagby and 
Taylor, 1997), which enables to establish empirically cut-off scores distinguishing 
alexithymic and non-alexithymic individuals (Taylor et al., 1988; Bagby et al., 1994a 
and 1994b; De Gucht and Heiser, 2003). Well-known measure of alexithymia presents 
self-reported questionnaire Toronto Alexithymia scale (TAS), but also other 
instruments for assesment of alexithymia have been developed. For example, other 
useful self-report instruments are the California Q-set (CAQ) (Haviland and Reise, 
1996), The Schalling-Sifneos personality Scale (SPSS) (Apfel and Sifneos, 1979), the 
MMPI alexithymia subscale (Kleiger and Kinsman, 1980), the Amsterdam Alexithymia 
Scale (AAS) (Bermond et al., 1999), Bermond-Vorst Alexithymia  Questionnaire 
(BVAQ) (Vorst and Bermond, 2001) and also a self-report observer Alexithymia Scale 
(OAS) (Haviland et al., 2000) that is completed by a subject‘s close person or relative. 
Several alexithymia clinical studies also enabled to develop structured interviews such 
as the Beth Israel Psychosomatic Questionnaire (BIQ) (Taylor et al., 1997), Alexithymia 
Provoked Response Questionnaire (APRQ) (Krystal et al., 1986), Karolinska 
Psychodynamic Profile (KAPP) (Weinryb et al., 1991) and other measures. As an 
important diagnostic complement for assesment of alexithymia may be used projective 
measures such as the Scored Archetypal Test (SAT9) (Cohen et al., 1985) or the 
Roschach (Acklin and Alexander, 1988). It is needed to mention that not all those 
measures have shown satisfactory psychometric characteristics (Linden et al., 1995; 





The self-report Toronto Alexithymia scale (TAS) is the first instrument that was made 
with concern for test development procedures and psychometric quality (De Gucht 
and Heiser, 2003). In the developing and improving of psychometric characteristics of 
TAS, subsequenly three versions of the TAS have been evolved:  first version was the 
TAS-26 (with 26 items), second version the TAS-R (Revised Toronto Alexithymia Scale 
with 23 items) and definite currently used version is the TAS-20 (with 20 items). All 
the versions of TAS differ from each other with respect to total number of items and 
factor structure (De Gucht and Heiser, 2003). The basic three dimensions of TAS 
included in all three versions are: (1.) difficulties to identify feelings and distinguish 
between feelings and bodily sensations (DIF), (2.) difficulties to describe feelings 
(DDF) and (3.) externally oriented thinking (EOT) (Bagby et al., 1994a, 1994b). 
Contrary to the TAS-26, alexithymia measured by the TAS-R and the TAS-20 is not 
totaly theoretically consistent with the alexithymia construct as originally it was 
defined because one of the subscales („reduced daydreaming“) was excluded from the 
subsequent versions of TAS because of theoretical incoherency with the other TAS 
subscales (De Gucht and Heiser, 2003). Although TAS-20 is reliable, valid and today 
most used meassure instrument it has several limitations (Taylor and Bagby, 2004). 
First of these limitations is that DIF and DDF represent very similar constructs 
(Kooiman, et al., 2002; Hintikka et al., 2001). In addition it has been found that the 
reliability of the EOT subscale is substantialy lower than other subscales (Bagby et al., 
1994a, 1994b; Kojima et al., 2001; Kooiman, et al., 2002) but as a result of various 
studies has been suggested that total score of TAS-20 presents valid and reliable 
measure and has been recommended by some authors for clinical assessment 
(Kooiman, et al., 2002). 
Another limitation of the TAS represents the fact, that personal standards might 
influence TAS score. For example it was observed that respondents with high levels of 
perfectionism scored higher on the TAS-20 (Lundh et al., 2002, Parling et al., 2010).  
In addition, alexithymia might be strongly influenced by depression and other 
psychopathological states (Wise et al., 1988; Honkalampi et al., 2000b, 2001b, 2010). In 
this context, later developed clinical instruments such as BVAQ or BIQ (Taylor et al., 
1997), have been found as less sensitive to a subjective  emotional state and they have 
been proved as  more specific alexithymia measures (Vorst and Bermond, 2001).  
Some researchers have also critized the TAS for not taking into account the affective   
component of alexithymia, and concentrating only on its cognitive component  
(Bermond et al., 2010). Although alexithymia concept includes cognitive as well as 
affective dimension (e.g. reduced emotionalizing and fantasizing) (Nemiah and 
Sifneos, 1970) the TAS scales mainly focus on the cognitive aspects of alexithymia 
(Bermond et al., 2010). In this context, some authors suggested that several 
psychological and physiological responses can be differently associated with affective 
and cognitive component of alexithymia, which could in principle present important 
limitation of all the TAS versions (Bermond et al., 2010). Therefore some new 
measures for alexithymia, as for example the BIQ (Taylor et al., 1997) or the BVAQ 





There is also evidence that TAS scores may vary across different populations and 
language versions (Dion, 1996; Kooiman et al., 2002; Le et al., 2002; Müller et al., 2003; 
Lumley et al., 2005).   
With respect to these limitations, some researchers (Kooiman, et al., 2002) 
recommended to use the TAS-20 together with the BIQ (Taylor et al., 1997) or the NEO 
Personality Inventory mainly the subscales focused on „openness feelings“ and 
„openness to fantasy“ (Costa and McCrae, 1992). Some authors also recommnend to 
use Observer Alexithymia Scale (OAS) [completed by a subject‘s close person or 
relative] together with TAS to obtain a more complex image of alexithymia (Dorard et 
al., 2008; Grandi et al., 2011).  
Several data suggest that there are also some other measures related to cognitive 
processing of emotions that may indirectly reflect alexithymia, for example Levels of 
Emotional Awareness Scale (LEAS) (Lane et al., 1990) or Kellner´s Emotional 
Inhibition Scale (EIS) (Grandi et al., 2011). The LEAS is a self-reported instrument 
evaluating written emotional responses to evocative interpersonal situations (Lane et 
al., 1998; Lumley et al., 2002; Subic-Wrana et al., 2005). Other similar measure related 
to cognitive processing of emotions represents Kellner´s Emotional Inhibition Scale 
(EIS) which is self rating scale focused on processes of conscious inhibition of 
emotional states (Grandi et al., 2011).  
 
 
            

























1.7. ETHIOLOGY OF ALEXITHYMIA 
 
Although numerous studies have reported associations between alexithymia and 
various somatic disorders, recently there are only few studies focused on the etiology 
of alexithymia. Originaly alexithymia construct has been developed in the field of 
psychoanalysis and applied in psychosomatic medicine, which determined that most 
of the studies concerned in the ethiology of the alexithymia have examined a role of 
psychological factors mainly related to childhood family factors etc. (Berenbaum, 
1996; Kooiman et al., 2004; Mason et al., 2005). Later research focused on several 
potential psychosocial, cultural and biological factors that likely play a role in 
ethiology of alexithymia suggests that ethiology of alexithymia is multifactorial, 
probably caused by combination of psychosocial and neurobiological factors but 
without results indicating reliable specificity of psychological and biological factors 




1.7.1. Psychosocial and cultural factors 
 
The role of the psychosocial factors in ethiology of alexithymia was mostly developed 
in the area of psychoanalysis which describe alexithymia as a defense mechanism 
(Krystal, 1979) as a result of deficit in emotional bonding and communication between 
mother (caregiver) and child leading to a limited differentiation of affects (Joukamaa 
et al., 2003). In this context, the importance of enviromental influences on children’s 
psychological development, especially “emotional climate” provided by parents 
(Nemiah, 1961) and secure attachment to parents (Fonagy and Target, 1997; Taylor et 
al., 1997) have been studied. The studies demonstrated, that insecure maternal 
attachment in early childhood (Gündel et al., 2002; Mason et al., 2005), poor family 
expressivenes during childhood (Berenbaum and James, 1994), overprotection by 
parents (Kooiman et al., 2004), born as unwanted child (Joukamaa et al., 2003), living 
in broken family (Joukamaa et al., 2007), general family pathology (Lumley et al., 
1996b), domestic violence (Modestin et al., 2005), and history of childhood abuse 
(Berenbaum 1996; Joukamma et al., 2008; Evren et al., 2009) may present an important 
role in pathogenesis of alexithymia. Intergenerational continuum of alexithymia in 
families supporting the role of psychological factors has been also observed (Lumley 
et al., 1996b; Fukunishi and Paris 2001; Grabe et al., 2008a).  
Several studies also proposed that some differences characterizing emotional 
expression and other differences related to socioeconomic and cultural factors related 
to education and social-economic status may play a role in alexithymia occurrence 
(Dion, 1996; Salminen et al., 1999). For example, increased alexithymia was observed 
in the group of Chinese speaking students compared with native English-speaking 
students (Dion, 1996) or people from Asian compared with the Caucasian people (Le 





symptoms in Asians compared with in Caucasians, which may be interpreted as a 
result of increased somatization of emotions among Asians (Le et al., 2002). It was also 
found that elevated alexithymia likely occur in the subjects living in rural areas 
compared to the urban areas (Joukamaa et al., 2003, 2007).  
Together these data suggest that alexithymia construct is valid and its measure is 
replicable in various socioeconomic, cultural and ethnic environments and in this 
context may represent universal psychological trait reflecting emotional processing 
and its conscious reflection (Taylor et al., 2003).  
                                            
 
 
1.7.2. Genetic factors of alexithymia 
 
Recent findings indicate that there are several potential pathways that could be 
responsible for the association between alexithymia and genetic factors (Plomin and 
Daniels, 1987, Plomin et al., 2008). In this context, some data suggest that some genes 
involved in transcription of neural receptors or neurotransmitters influencing and 
modulating neurodevelopment could play a role in variation of alexithymia 
expression (Picardi et al., 2011). For example, an association between alexithymia and 
the stress-related catechol O-methyltransferase Val108/158Met gene polymorphism 
(Ham et al., 2005) has been found. Also few family studies and four genetic twin 
studies of alexithymia suggest that intergenerational transmission of alexithymia 
based on genetic factors may occur (Heiberg and Heiberg, 1978; Valera and 
Berenbaum, 2001; Grabe et al., 2008a). For example, significant contribution of genetic 
factors to interindividual differences in alexithymia has been found in two 
population-based studies with large groups of twin pairs published by Jørgensen et al. 
(2007) and Picardi et al. (2011).  In the Picardi’s et al. study genetic factors were 
accounted to be responsible for almost 42% of individual differences in alexithymia 
and they found significant “genetic correlation” between alexithymia and depression. 
They also found probable genetic link between alexithymia and depression (Picardi et 
al., 2011) which are frequently associated (Parker et al., 1991; Marchesi et al., 2000; 




1.7.3. Neuropsychology of alexithymia 
 
According to some authors alexithymic features can be the caused by different neural 
dysfunctions, which might result in dysregulation of emotional-physiological 
responses (Bermond et al., 2006). The fundamental neural structures which relevance 
for alexithymia is predominantly discussed are right and left hemisphere (Ross and 
Rush, 1981; Weintraub and Mesulam 1983; Taylor, 1984; Fricchione and Howanitz, 





al., 2003; Kano et al., 2003), corpus callosum (Galin, 1974; Hoppe and Bogen 1977; 
Buchanan et al., 1980; Tenhouten et al., 1985, 1986; Krystal, 1988; Zeitlin et al., 1989; 
Dewaraja and Sasaki, 1990; Ernst et al., 1999; Parker et al., 1999; Lumley and Sielky 
2000; Huber et al., 2002; Grabe et al., 2004; Richter et al., 2006; Romei et al., 2008;  Lang 
et al., 2011), anterior commissure (Bermond et al., 2006), anterior cingulate cortex 
(Lane et al., 1997;  Lane et al., 1998; Corbetta et al., 1990, 1991; Frith et al., 1991; Paus et 
al., 1993;  Devinsky et al., 1995; Phan et al., 2002; Gündel et al., 2004b; Bermond et al., 
2006), prefrontal cortex (Krystal 1988; Kolb and Whishaw 1990; McDonlad and 
Prkanin 1990; Aftanas et al., 2003; Kano et al., 2003; Bermond et al., 2006), amygdala 
(Berthoz et al., 1999; Iversen et al., 2000; Kano et al., 2003; Bermond et al., 2006; Kugel 
et al., 2008; Sato et al., 2008), and insular cortex (Huber et al., 2002; Kano, et al., 2003; 
Silani et al., 2008).  
 
 
                             
1.7.3.1. Alexithymia and right/left hemisphere 
                              
Results of numerous studies indicate that in most righ-handed subjects the verbal, 
conscious and serial information processing takes places in the left hemisphere and 
the unconscious, non-verbal and parallel holistic information processing takes place in 
the right hemisphere (Tucker et al., 1986; Miller, 1986-1987; Gazzaniga 1989). In 
context of emotional processing it is considered that right hemisphere is included 
predominantly in subjective emotional experience, memorising emotions, 
communication of emotions to others, and emotional physiological responses while 
the left hemisphere is supposed to serve to analysis emotions and higher explicit 
emotional cognitions (Ross and Rush 1981; Fricchhione and Howanitz 1985; Adolphs 
et al., 2000).  In this context it was suggested that inbalance in activation between both 
hemispheres (hypoactive right hemispehere, or hyperactive left hemisphere) can be 
implicated in etiopathogenesis of alexithymia (Weintraub and Mesulam 1983; Taylor, 
1984; Berenbaum and Prince, 1994). For example it was found that patients with large 
postraumatic right unilateral cortical lesions are not able to describe their own 
emotional responses, while are able to describe emotional reactions of others as well 
as their present emotional reactions from the time before their accident (Ross and 
Rush, 1981; Fricchione and Howanitz, 1985). Similar observations in the patients with 
right unilateral hemispheral strokes were found (Spalletta et al., 2001). The role of 
hemispheric functions in alexithymia was also confirmed in the studies of conjungate 
lateral eye movements (CLEMs), which are considered to be indicators of relative 
hemispheric activations. The CLEMs studies have demonstrated relative higher right 
hemisphere activation in alexithymic subjects (Parker et al., 1992). Also some further 
studies have shown that brain activity in alexithymic subjects, indicated by PET 
(Positron Emission Tomography) is decreased in the neocortex of the right hemisphere 
and conversely increased in the left brain regions (Kano et al., 2003).  There are also 





emotions in alexithymia which was interpreted as a sign of "electrocortical effort" 
reflecting difficulties in symbolization of emotion and resulting from impaired right-
hemispheric emotional processing (Aftanas et al., 2003). In this context, there is 
evidence that alexihymic subjects process emotional words, presented to the right 
hemisphere, predominantly in their left hemisphere, in contrast to nonalexithymic 
that process such information in right hemisphere (Bermond et al., 2006). On the other 
hand few hemispheric specialization studies that did not find a right hemisphere 
dysfunction in alexithymic subjects were also published (Cole and Bakan, 1985; Grabe 
et al., 2004). All these data suggest valuable hypothesis for future research, that 
alexithymia is related to a dysfunction of the right hemisphere although the curent 




1.7.3.2. Alexithymia and interhemispheric transfer 
                              
In the previous research the relationship between alexithymia and interhemispheric 
information transfer via the corpus callosum and the anterior commissure was 
examined. Data of these studies indicate that the right hemisphere seems to be 
predominant in perception and motor expression of emotion and uncoscious 
nonverbal information processing (Ross and Rush 1981; Fricchhione and Howanitz 
1985; Adolphs et al., 2000). Together recent data resulted in a hypothesis that 
neurophysiological corelate of alexithymia could represent a case of “functional 
commisurotomy” (Galin, 1974; Krystal, 1988; Parker et al., 1999; Lumley and Sielky 
2000). For example, several case studies in patients with corpus callosum agenesis 
reported increased alexithymia scores in this group of patients (Buchanan et al., 1980; 
Ernst et al., 1999).  
Similarly, increased alexithymia scores was observed in patients after commisurotomy 
(Hoppe and Bogen 1977; Tenhouten et al., 1985, 1986) and some studies have shown 
that the degree of interhemisferic transmission is significantly correlated with 
alexithymia and its subscales, but only in men (Zeitlin et al., 1989; Lumley and Sielky 
2000). In this context, some PET studies found both decreased activation of corpus 
callosum after actively remembering on emotional experiences (Huber et al., 2002) and 
increased activation of corpus callosum by passively watching faces with emotional 
expressions (Kano et al., 2006). Slowering of transcallosal conduction time in 
alexithymic subjects was also demonstrated in some studies (Dewaraja and Sasaki, 
1990; Romei et al., 2008) and taken together these results emphasize functional 
differences in transcallosal interactions in high alexithymic subjects and supported the 
hypothesis of the interhemispheric transfer deficit in alexithymia.  
On the contrary few studies indicating that alexithymia is related to the facilitation of 
transcallosal transfer in the both interhemispheric transfer directions were published 
(Grabe et al., 2004; Richter et al., 2006; Lang et al., 2011). Grabe et al. (2004) also found 





specific differences could be explained by the hypothesis that cerebral functions are 
less lateralized in females than in males (Bradshaw, 1989; Zeitling et al., 1989; Canli et 
al., 1998; Lumley and Sielky, 2000). Based on these findings, results indicating  
facilitated transcallosal inhibition (Grabe et al., 2004; Richter et al., 2006; Lang et al., 
2011) suggest a neurobiological model focused on explanation how facilitated 
interhemispheric inhibition of  right and left hemisphere lead to difficulties in 
emotional processing, decreased ability to verbalize emotional contents, and 
presumably also in an externally oriented cognitive thinking style. Authors of 
facilitated cortical inhibition concept hypothesis suggest that the more expressed left 
cortical inhibition results in a difficulty in expressing feelings, while a right cortical 
inhibition results in an externally orienting cognitive style. Base on these results of it 
has been proposed that facilitated cortical inhibition model may represent a 
neurobiological correlate of alexithymia (Grabe et al., 2004; Richter et al., 2006; Lang et 
al., 2011).  
In addition, Gazzaniga and LeDoux (1978) imply that also persons with commissure 
anterior dysfunction are not able to experience emotional feelings however they have 
access to accompanying cognitions. In this context, these data suggest that in anterior 
commisurotomy patients the cognitive components of stimuli reach the conscious left 
hemisphere through the corpus callosum, while the emotional values first projected to 
the limbic system and from there projects to the left hemisphere by anterior 
commisure (Bermond et al., 2006). Anterior commisure connects the amygdala and the 
paleo-cortical parts in both hemispheres, as well as as the anterior temporal lobes, a 
part of the temporal lobe, to which the corpus callosum does not project (Kolb and 
Whislaw, 1990). According to Bermond et al. (2006) today is not sufficient information 
concerning this issue and to date there is no study connecting the anterior commisure 
directly to alexithymia. Moreover most of the alexithymia studies used TAS, which 
does not meassure reduction of emotionalising (reduction of affect), which is expected 
in commisura anterior dysfunction (Bermond et al., 2006). In summary the hypothesis 
that alexithymia is associated with alterations of interhemispheric transfer of 




1.7.3.3. Alexithymia and anterior cingulate cortex 
 
There is evidence that ventral and dorsal parts of anterior cingulate cortex (ACC) are 
involved in the affective and cognitive processing of emotions in alexithymia (Lane et 
al., 1997; Bermond et al., 2006).  Several authors suggest that individual variations in 
the ability to properly recognise emotional signals may be a function of the degree to 
which the ACC is able to participate in the processing and response to emotional cues 
(Lane et al., 1997). The role of the ACC in the conscious awarness of emotion has also 
been suggested (Lane et al., 1997).  The results from a PET study by Lane et al. (1998) 





aggrement with previous observations showing activity of ACC increasing as a 
function of attention or conscious awareness with respect to cognitive stimuli 
(Corbetta et al., 1990, 1991; Frith et al., 1991; Paus et al., 1993). These data are also 
consistent with the finding that approximately 50% of post-cingulotomy patients have 
blunted affects postoperatively (Devinsky et al., 1995). In addition, some studies have 
found that reduced size of right ACC on MRI is positively correlated with TAS score 
in healthy men (Gündel et al., 2004b). On the other hand there are some studies that 
are equivocal with the previous findings. For example meta-analysis of PET or fMRI 
studies has shown that positive emotions activate basal ganglia, but not ACC (Phan et 
al., 2002). In conclusion, the results of presented studies are not consistent, and the 
role of ACC in processing of emotions as well as in alexithymia is still not fully 




1.7.3.4. Alexithymia, prefrontal cortex and amygdala 
                           
An important role of the prefrontal cortex (PFC) in emotional experience presents well 
known observation (Krystal 1988; Kolb and Whishaw 1990; McDonald and Prkachin, 
1990). In this context, Trigg (1970) demonstrated that, after frontal lobotomy, the 
reality is interpreted as before however, these interpretations are accompanied with 
no emotional feelings. It was observed that patients with prefrontal lesions exhibit a 
reducted facial expression and a depleted fantasy-life, which is typical alexithymic 
feature (Krystal 1988; Kolb and Whishaw 1990; McDonald and Prkachin, 1990). It has 
also been shown that in response to emotional stimuli alexithymic subjects 
have decreased event related potentials (ERPs) in frontal left hemisphere (Aftanas et 
al., 2003). Similarly the PET study by Kano et al. (2003), found decreased activations in 
the right orbitofrontal cortex (O-FC) in alexithymic subjects in reaction to negative 
emotional stimuli. It was supposed that both orbital and mediotemporal 
orbitoprefrontal cortices have significant role in affective aspects of alexithymia, while 
right temporal cortex has functions in cognitive aspects (Bermond et al., 2006).  
In addition, the role of amygdala in alexithymia is also discussed and considered to 
play a key role in processing of emotional stimuli and emotional experience. Various 
studies indicated that the amygdala is involved in detection of emotional significance 
of stimuli (Ono et al., 2000; Adams et al., 2003) and in recognition of emotional facial 
expressions (Lerner et al., 2012). The amygdalae are involved in both cognitive and 
affective functions (Bermond et al., 2006). There are however only few studies 
examining amygdala in alexithymia. Berthoz et al. (1999) and Kano et al. (2003) failed 
to find alexithymia related differences in amygdala function. Another study of Kugel 
et al. (2008) have found that the difficulties with identifying feelings are negatively 
correlated with function of the right amygdala in response to the negative emotional 
stimuli, even when controlling for depressivity and anxiety. For example, decreased 





in patients with the amygdala lesions (Sato et al., 2008). In this context it was 
hypothesized that L-DOPA may potentialy activate dopaminergic systems involved in 
recognition of emotion such as the medial prefrontal cortex (M-PFC) and ACC, and 
compensate the amygdala dysfunction or activate intact portions of the amygdale 
(Sato et al., 2008). According to Bermond et al. (2006) on the base of previous research 
amygdala is primarily involved in implicit processing and identifying emotions as 
well as explicit identifying emotions. Bermond et al. (2006) suggest that subjects with 
extremely low capacities to emotionalise would show, in response to emotional 
stimuly, strong activation in amygdala, and vice versa. Concerning the relationship 
between amygdala and PFC it is known, that M-PFC and O-FC are related to 
emotional feeling (Bermond et al., 2006), whereas the amygdala mediates both 
emotional physiological and inborn, and acquired behavioral responses (Iversen et al., 
2000). It is hypothesized that if the M-PFC did not inhibit the amygdala, then this 
phylogenetically older structure would initiate preprogrammed emotional behaviour 
(Bermond et al., 2006). 
 
 
                                       
1.7.3.5. Alexithymia, insular cortex and other brain areas 
 
Only few studies examining relationship between insula and alexithymia have been 
published. For example, hypoactivation of insula in response to angry in alexithymic 
subjects was observed (Kano, et al., 2003). Also the study by Silani et al. (2008) found 
that degree of the ability to understand its own emotions is positivelly correlated with 
activity in the anterior insula. Few previous studies  associated insular functions with 
regulation of negative emotional experiences, such as pain, distress, hunger, thirst, 
fear, anger, sadness and disgust (Hennenlotter et al., 2004), emotional decision making 
(Ernst et al., 2003), and production of facial emotional expressions (Carr et al., 2003). It 
was also reported that alexithymia is related to hypoactivation in the right inferior 
parietal and occipital cortices, and hyperactivation in left inferior parietal cortex and 
cerebellum in response to emotional stimuli have been observed (Kano et al., 2003). 
There is also evidence that higher activation in cuneus and precuneus, thalamus, right 
inferior temporal and left superior temporal regions, and cerebellum in alexithymia 




1.7.3.6. Alexithymia and emotion processing abnormalities 
 
Recent neurophysiological research focused on evoked potentials provides evidence 
that alexithymia is related to the impaired processing of emotional stimuli. Franz et al. 
(2004) found association between alexithymia and deficit in processing of emotional 





cortical regions in response to emotional stimuli in alexithymic subjects was also 
found (Aftanas et al., 2003; Aftanas and Varlamov, 2004, 2007). Some other studies 
have indicated that also early perceptual-related processes are altered in alexithymia 
(Schaefer et al., 2007; Pollatos and Gramann, 2011). The authors of theses studies 
explained this observation by a hypothesis that alexithymia may be associated with a 
general stimulus augmentation to prevent alexithymic subjects by ignoring stimuli 
that might be dangerous. This mechanism is also hypothesized as responsible for the 




1.7.3.7. Summary of the neuropsychological studies in alexithymia 
 
Based on current findings Bermond et al. (2006) suggest that the right hemisphere 
produces a global, nonverbal overview of emotional information and that the left 
hemisphere analyses emotions and higher explicit emotional cognition. According to 
them neural structures mostly important in the affective aspects of alexithymia are the 
amygdala, both orbitoprefrontal cortices and the two subparts of anterior cingulate. 
On the other hand neural structures important for the cognitive aspects of alexithymia 
are only partially different and include right temporal cortex, two subparts of anterior 
cingulate and also the amygdala (Bermond et al., 2006).  But although some specific 
structures may be involved in alexithymia more than the others, in principle current 
findings indicate that likely all brain structures are involved in processing related to 
consciousness (Balduzzi and Tononi, 2008), can modulate one another and create 
systems of mutual connections and dependences. In this context, alexithymia present 
specific form of disordered consciousness characterized by a disturbed conscious 
emotional processing. 
 
              
 

















1.8. ALEXITHYMIA AND MENTAL HEALTH 
 
1.8.1. Alexithymia and depression 
  
Although alexithymia was first studied in relationship to the psychosomatic illnesses 
(Taylor et al., 1999) majority of recent research studies is mainly focused on 
alexithymia symptoms in various psychopathological states, such as depression, 
anxiety, psychotic episodes etc. Most investigated topic in this area of the research 
actually is the relationship between alexithymia and depression. Numerous studies 
have demonstrated that alexithymia and depression are strongly associated in both 
general and clinical populations (Wise et al., 1990a, 1990b, 1995; Hendryx et al., 1991; 
Taylor et al., 1999; Honkalampi et al., 1999, 2000a, 2000b, 2001a, 2004; Le et al., 2007; 
Tolmunen et al., 2011). It has been shown that 39% to 46 % of patients with major 
depression are alexithymic (Honkalampi et al., 1999, 2000a; Saarijarvi et al., 2001, 2006) 
and that presence of alexithymia in major depression patients is associated with 
severity of depression and suicide risk (Bankier et al., 2001; Saarijarvi et al., 2006). 
According to these studies, average Pearson correlation coeffiecient between 
depressive symptoms (BDI) and alexithymia (TAS-20) is around 0.25-0.56 (Hintikka et 
al., 2001; Yalug et al., 2010; Tolmunen et al., 2011). The correlations were even higher 
in the alexithymic individuals with higher ratings of depressive symptoms (Hintikka 
et al., 2001; Tolmunen et al., 2011). The results of numerous studies have also shown 
that the correlations between depression, and alexithymia are high across time and 
that there are parallel changes of TAS-20 scores and BDI in a follow-up studies 
(Honkalampi et al., 2001b; De Timary et al., 2008a; Marchesi et al., 2008, Tolmunen et 
al., 2011). 
Because of strong positive correlation between alexithymia and negative affects some 
authors have concluded that alexithymia could be secondary to depression, or other 
psychopathological states (Haviland et al., 1988 and 1991). On the other hand some 
studies have reported relative independence of alexithymia and depressive symptoms 
(Hintikka et al., 2001; Tolmunen et al., 2011) and factor analysis have shown that 
alexithymia and depression represent distinct psychological constructs (Parker et al., 
1991; Hintikka et al, 2001). It was also found that the TAS-20 and BDI-II items based 
on separate factors are overlapped only in minority (Hintikka et al, 2001). In this 
context, there are few studies documenting that alexithymia may present a risk factor 
of depressive symptoms (Taylor and Bagby, 2004; Tolmunen et al., 2011). In contrast 
to these findings there is some interesting data that has not found alexithymia as a 
predictor of depresive episodes in women during pregnancy (Marchesi et al., 2008). In 
addition, some authors have reported that alexithymic scores can decrease from the 
acute to the remission phase of depression (Taylor and Bagby, 2004; Saarijarvi et al., 
2006; Le et al., 2007).  
 
 





                      
1.8.2. Alexithymia and other psychopathological states 
 
Several studies have demonstrated a positive association between alexithymia and 
various other psychopathological symptoms, for example relationship of alexithymia 
with anxiety symptoms and disorders in clinical as well as non-clinical samples 
(Yehuda, et al., 1997; Berthoz  et al., 1999; Badura, 2003; Tutkun et al., 2004; Marchesi 
et al., 2005; Mennin et al., 2005; Spitzer et al., 2007; Evren et al., 2008; De Timary et al., 
2008a; Frewen et al., 2008a, 2008b; Galderisi et al., 2008, Tselebis et al., 2010; Yalug et 
al., 2011) and also with obsessive-compulsive disorder (OCD) (De Berardis et al 2005; 
Grabe et al., 2006; Roh et al., 2011).  
In addition, numerous studies of adult and adolescent populations have demonstrated 
a strong association between dissociative symptoms and alexithymia (Berenbaum and 
James, 1994; Grabe et al., 2000; Elzinga et al, 2002; Lipsanen et al., 2004; Tutkun et al., 
2004; Maaranen et al. 2005; Mason et al., 2005; Sayar et al., 2005; Evren et al., 2007; 
Evren et al., 2008; Simeon et al., 2009; Tolmunen et al., 2010). In this context it was 
suggested that some symptoms as well as potential ethiological mechanism of 
dissociation and alexithymia might be partially shared (Berenbaum, 1996; Simeon et 
al., 2009).  Some researchers explained the relationship between dissociation and 
alexithymia by mediating factors such as depression (Zlotnick et al., 1996; Wise et al., 
2000; Tutkun et al., 2004). Taken together majority of the studies suggest that 
alexithymia and dissociation present partially overlapping but different phenomena 
(Berenbaum and James, 1994; Wise et al., 2000; Lipsanen et al., 2004, Evren et al., 2007, 
Tolmunen et al., 2010).  
Several studies have also found that alexithymia is related to symptoms of eating 
disorders (Corcos et al., 2000; Eizaguirre et al., 2004; Bydlowski et al., 2005; Parling et 
al., 2010) and reported that prevalence of alexithymia in this population is between 23-
77% (Eizaguirre et al., 2004). There are some studies  emphasizing that alexithymia 
might be mediated by negative affects (such as depression and/or anxiety) in this 
group of patients (Bydlowski et al. 2005; Montebarocci et al., 2006; Parling et al., 2010).  
Several studies also support associations of alexithymia with alcohol dependence 
(Loas et al., 1997; Sakuraba et al., 2005; De Timary et al., 2008a; Evren et al., 2008), 
substance abuse (Troisi et al., 1998; Farges et al., 2004; Speranza et al., 2004) or internet 
addiction (De Berardis et al., 2009). For example, the prevalence of alexithymia among 
alcoholic patients is increased, amounted to be approximately from 40 to 60% 
(Haviland et al., 1988, 1994; Cecero and Holmstrom, 1997; Taieb et al., 2002). In this 
context, two longitudinal studies (Ziolkowski et al., 1995; Loas et al., 1997) have 
demonstrated that higher alexithymic features at onset of withdrawal are predictors of 
relapse 12 to 15 months afterwards which indicate that alexithymia could represents 
one of the important risk factors for the relapse of alcoholism. On the other hand some 
studies have shown alexithymia as a state phenomenon secondary to the depressive 





There are also studies that have documented relationships between alexithymia and 
schizophrenia (Maggini and Raballo, 1994; Stanghellini and Ricca, 1995; Nkam et al., 
1997a, 1997b). It has been shown that schizophrenia patients with predominant 
negative symptoms have significantly higher alexithymia (Nkam et al., 1997a, 1997b). 
For example, alexihymia was related to self-experienced language impairments in 
nondeficit schizophrenic patients and to the severity of schizophrenia (Stanghellini 
and Ricca, 1995). Recent data also suggest that alexithymia in schizophrenia is more 
heterogeneous than was previously recognized, and has several components, some of 
which are more state-related, and others of which are  more like trait features 
(Maggini and Raballo, 2004). 
Current data indicate that prevalence of alexithymia is also significantly higher in 
borderline-personality disorder (Guttman and Laporte 2002; Modestin et al., 2004, 
2005) and autism spectrum disorder (Hill et al., 2004; Tani et al., 2004; Silani et al., 
2008). In addition several data suggest that alexithymia is also linked to decreased 
quality of life (Mattila et al., 2010b), sleep disturbances (Bazydlo et al., 2001; Kronholm 




1.9.   ALEXITHYMIA AND SOMATIC HEALTH 
 
Recent findings indicate that patients with broad spectrum of somatic disorders are 
more alexithymic than controls and large amount of the studies have documented 
significant association between alexithymia and physical illness. For example, it has 
been reported that prevalence of alexithymia is 13,8-37,1% in multiple sclerosis 
patients  (Bodini et al., 2008; Prochnow et al., 2011), 33-53% in patients with various 
types of persistent pain (Millard and Kinsler, 1992; Cox et al., 1994; Lumley et al., 
2002), 21-24% in Morbus Parkinson patients (Costa et al., 2006, 2010; Poletti et al., 
2011), 56% in patients with functional gastrointestinal disorders (Porcelli et al., 2003), 
90% in patients with non-epileptic seizures (Bewley et al., 2005) and 31% subjects 
undergoing upper endoscopy (Mandarelli et al., 2011). Higher prevalence of 
alexithymia has been also found in patients with psychogenic pain (Sriram et al., 
1987), inflammatory bowel disease (Porcelli et al., 1995),  essential hypertension 
(Todarello et al., 1995; Jula et al., 1999), rheumatoid arthritis (Bruni et al., 2006; 
Vadacca et al., 2008),  inflammatory bowel disease (Porcelli et al., 1996), migraine 
(Muftuoglu et al., 2004; Yalug et al., 2010), bronchial astma (Serrano et al., 2006), 
chronic obstructive pulmonary disease (Tselebis et al., 2010), female breast cancer 
(Manna et al., 2007), psoriasis (Conrad et al., 2008), diabetes mellitus (Topsever et al., 
2006), cardiac events and fatalities in postmyocardial infarction patients (Berensvaite 
et al., 2000) and somatisation (de Gucht and Heiser, 2003).  
The important shortcoming of these findings presents the fact that psychopathological 





also few studies that have not found any relationship between alexithymia and somatic 
illnesses (Ahrens and Defner, 1986).   
                                     
 
 
1.10. ALEXITHYMIA AND PAIN 
 
Several psychopathological symptoms, including alexithymia may be understood as 
predictors in the onset, chronification, recurrence, and responsiveness to treatment of 
pain disorders, however, much uncertainty still remains about the weight and 
functions of these psychological factors (Mehling and Krause, 2007).  In this context 
the association between alexithymia and various pain conditions has been 
demonstrated in numerous studies. For example, elevated prevalence (33 to 53% 
patients) of alexithymia among patients with chronic or persistent pain has been 
observed (Millard and Kinsler, 1992; Zayfert et al., 1992; Cox et al., 1994; Lumley et al., 
2002; Sayar et al., 2004; Glaros and Lumley, 2005; Hosoi et al., 2010). In addition, it has 
been found that alexithymia is positively correlated with acute pain severity and 
experimental pain tolerance in healthy controls (Nyklicek and Vingerhoets, 2000; 
Putterman et al., 2001). Alexithymia has also been shown to predict depression 
(Kosturek et al., 1998; Lumley et al., 2002), anxiety (Kosturek et al., 1998), and physical 
impairment (Lumley et al., 2002) in patients with various chronic pain conditions and  
might represents a risk factor for chronic pain, disability, and related health problems 
in pain patients (Lumley et al., 2002).  
Alexithymia is also positively correlated with pain symptoms in patients with chronic 
myofascial pain (Lumley et al., 2002), temporomandibular disorder (Glaros and 
Lumley, 2005), rheumatoid arthritis (Fernandez et al., 1989; Lumley et al., 2005), 
migraine headaches (Lumley et al., 2005; Yalug et al., 2010), systemic lupus 
erythematosus (Lumley et al., 2005), fibromyalgia (Leichner-Hennig and Vetter, 1986; 
Sayar et al., 2004; Huber et al., 2009), cancer pain (Porcelli et al., 2007), psychogenic 
pain (Sriram et al., 1987), inflammatory bowel disease (Porcelli et al., 1995), higher 
pain intensity and interference in chronic neuromuscular pain patients (Hosoi et al., 
2010) and several other types of pain disorders. In this context, several studies have 
also found association between alexithymia and LBP (Low Back Pain) (Julkunen et al., 
1988; Acklin and Bernat, 1987; Kinder and Curtiss, 1990; Viikari-Juntura et al., 1991; 
Mehling et al., 2005).  
Worthy of mentioning are observations that in majority of pain studies there are 
substantial individual differences in both alexithymia levels and pain severity among 
people with chronic pain. Only approximately 25-50% of the chronic pain patients 
were alexithymic, suggesting that there is much variability in alexithymia among 
people with chronic pain (Lumley et al., 2002). According to previous data, degree of 
alexithymia should correlate positively with the severity of pain. The evidence for this 
relationship is however equivocal and there are some studies that have not found any 





et al., 1992; Cox et al., 1994; Lumley et al., 2005; Celikel and Saatcioglu, 2006; Friedberg 
and Quick, 2007; Van Middendorp et al., 2008). In addition, there are recent data 
documenting that alexithymia is related to the affective but not sensory dimension of 
pain (Lumley et al., 2002). The possible explanation of these equivocal results is the 
multidimensional character of pain, which includes a sensory component (intensity 
and temporospatial characteristics) and also affective or unpleasantness components 
(Melzack and Katz, 1999). Differentiating these two dimensions seems to be important 
because they are affected by different psychological and biological processes (Melzack 
and Katz, 1992). In summary, current data suggest that alexithymia is associated with 
increased affective pain and hypochondriacal illness behavior which could be 
mediated, by psychological distress (Hubera et al., 2009). These observations could 
represent a response to a question, why many studies failed to find an association 




1.11. ALEXITHYMIA AND PSYCHOTHERAPY 
 
Recent findings indicate that about quarter of an all patients involved in a 
psychotheraphy are alexithymic and that alexithymia predicts poor therapeutic 
outcome (Sifneos 1973).  
Already the study of Karush et al. (1969) has tested an effect of psychotherapy in 
subjects with ulcerative colitis and showed that the majority of these patients (80%) 
exhibit a behavioral pattern strongly suggestive of alexithymia and typically 
manifested by emotional restriction and unresponsiveness to insight-oriented 
psychotherapy. Similarly a significant role of alexithymia in psychoterapeutic 
treatment of posttraumatic stress disorder (PTSD) has been found (O'Brien et al., 
2008). In addition, several further studies have also reported poorer psychotherapy 
outcome in alexithymic individuals (Sifneos 1973; Freyberger 1977; Taylor 1997; Páez 
et al. 1999; Solano et al. 2003).  
On the other hand, numerous data indicating conversely positive effect of 
psychotherapy in alexithymia have been reported. For example, a study was reported 
in which on 297 psychodynamic group therapy inpatients has been demonstrated that 
psychodynamic group therapy may lead to signifiant amelioration of alexithymic 
features (Grabe et al., 2008b). In addition, Beresnevaite (2000) observed a significant 
reduction in alexithymia after modified group psychotherapy in post myocardial 
infarction patients. Similarly Gay et al. (2008) reported interesting data suggesting 
reduction of alexithymia in hypnotherapy using hypnotic imagery.  
In addition, several psychotherapy interventions focused on amelioration of 
alexithymia have been sucesfully tested and supported creative use of counter-
transference (Taylor, 1977), helping the patients to observe the nature of their 
alexithymic disturbances (Krystal, 1979, 1982-83), empathetic reactions from a 





alexithymic patiens] (Rosenblum et al., 2005), positive reactions from therapist 
(Ogrodniczuk et al., 2005), short-term supportive or interpretative individual  therapy 
or group psychotherapy focused on patients with lower levels of alexithymia 
(McCallum et al., 2003), cognitive rather than psychodynamic therapies (Lumley et al., 
2007) and some others  (Kennedy and Franklin, 2002; Simha-Alpern, 2007; Tulipani et 
al., 2011). On the other hand, there are also several studies that have not supported 
negative effect of alexithymia on psychotherapeutic outcome (Lumley, 2004; Spek et 




1.12. ASSOCIATION OF ALEXITHYMIA WITH WORSE HEALTH 
 
Previous research have shown a significant association between alexithymia and 
worse physical and mental health functions, and studied some mechanisms of this 
association, and processes potentially responsible for this relationship via 
physiological, behavioral, cognitive or social pathways (Lumley et al., 1996a). In this 
context, relationship of alexithymia with physiological dysregulation of autonomic, 
neuroendocrine and immune system dysregulation is mostly discussed.  It was 
suggested that alexithymic subject fail to regulate emotions, particulary negative, 
which results in chronic alterations of autonomic, endocrine and immune system 
(Lane et al., 1997; Guilbaud et al., 2009). 
Behavioral pathway presents a source of health problems mainly through potentially 
unhealthy behaviors (Lumley et al., 1996a; Lumley et al., 2007), such as disturbed 
eating (Bydlowski et al., 2005; Speranza et al., 2007), poor nutrition and sedentary 
lifestyle (Helmers and Mente, 1999), alcohol consumtion (Loas et al., 1997; Sakuraba et 
al., 2005; De Timary et al., 2008a; Evren et al., 2008) other substance abuse (Troisi et al., 
1998; Farges et al., 2004; Speranza et al., 2004), internet addiction (De Berardis et al., 
2009), obesity (Da Ros et al., 2011) or unprotected sex, sleep loss, and nonadherence to 
medical regimens (Lumley et al., 1996a). In this context, cognitive pathway in 
alexithymia may potentially influence health by somatic amplification, somatisation, 
increased seeking of medical care and also various social influences, such as impaired 









Figure 1a. Overview of potential pathways linking alexithymia and worse health. 
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1.12.1. Alexithymia and autonomic nervous system 
 
According to current findings alexithymia is linked with weakened conscious 
experience of emotions manifesting in specific responses of the autonomic nervous 
system (ANS), for example response to emotion-evoked stimuli in alexithymic 
subjects are exaggerated or excessively persistent (Nemiah, 1975; Martin and Pihl, 
1985; Papciak et al., 1985; Gross, 2002; Thayer and Brosschot, 2005).  
Current findings show some specific processes related to autonomic changes in 
alexithymia which enabled to formulate three basic theoretical approaches. First 
theory presents the so-called “decoupling hypothesis” (Papciak et al., 1985) suggesting 
that alexithymia is associated with decoupling of peripheral physiological activity and 
accurate report of feeling state, particulary in response to stress, which result in 
physiologic dysregulation. Second hypothesis presents the discharge hypothesis that 
posits inverse relationship between outward expresion of an emotion and the inward 
autonomic response at any level of emotional stimulation.  This conceptualisation 
suggests that inhibition of expression of emotions cause increased sympathetic 
activation (Jones, 1935; Cacioppo et al., 1992). Third main explanation presents 
alexithymia-stress hypothesis (Martin and Pihl, 1985) suggesting that the influence of 
alexithymia on the expression of stress-related pathological states might involve poor 
resistance to stress. According to this hypotheses, poor resistance to stress stimuli in 
alexithymia results in dysregulation of autonomic and neuroendocrine system. 
Several recent studies also reported basic support for “hypoarousal theory” 
suggesting that conversely decreased sympathetic responses to emotional provocation 
in alexithymic individuals may occur (Linden et al., 1996; Bermond et al., 2010).  
In agreement with hyperarousal theories, several studies have found relationship 
between alexithymia and increased baseline levels of sympathetic activation (Martin 
et al., 1986; Martin and Pihl, 1986; Rabavilas, 1987; Wehmer et al., 1995; Infrasca, 1997; 
Fukunishi et al., 1999; Gündel et al., 2004a; Bagby et al., 2009). For example, it has been 
found higher baseline hearth rate (Papciak et al., 1985; Wehmer et al., 1995) and 
greater tonically basal electrodermal activity (Rabavilas, 1987; Friedlander et al., 1997) 
in alexithymic individuals. But several studies did not confirm these results (Hyer et 
al., 1991; Newton and Contrada, 1994; Roedema and Simons, 1999). 
Several studies performed in alexithymic individuals have found decreased 
autonomic responses to stress stimuli (Newton and Contrada, 1994; Wehmer et al., 
1995; Friedlander et al., 1997; Fukunishi et al., 1999; Roedema and Simons, 1999). On 
the other hand some studies have found conversely increased autonomic responses 
(Papciak et al., 1985; Martin and Pihl, 1986; Infrasca, 1997; Gündel et al., 2004a; Bagby 
et al., 2009) or unchanged autonomic responses to stress stimuli in alexithymic 
subjects (Rabavilas 1987; Connelly and Denny, 2007).   
Althougt, previous data examining tonic and reactive autonomic functioning in 
alexithymia are not fully consistent, majority of these studies reported that 
alexithymia is associated with increased sympathetic baseline levels and decreased 





1.12.2. Alexithymia and neuroendocrinne functions 
 
One of the first studies documenting neuroendocrine response in alexithymia was 
published by Lindholm et al., (1990) in a sample of 266 healthy adults. The authors 
have demonstrated statistically significant association between alexithymia (BIQ) and 
abnormal elevated serum cortisol levels following dexamethason administration, 
which likely indicates an aberrant stress reaction of hypothalamo-pituitary-adrenal 
(HPA) axis in alexithymic individuals. Worth of the mentioning is the fact that results 
of the study were unchanged after controlling for depression (PSE-CATEGO), age, 
social ranking, marital status and other demographic data (Lindholm et al., 1990). 
Another study by Finset et al. (2006) performed on fibromyalgia patients has shown 
that an increase in depressed affect (POMS) from pre to post-stress stimulus was 
associated with significant increase of salivary cortisol, but only in female patients 
with alexithymia (TAS-20).  Suprisingly the increase of salivary cortisol levels was not 
observed immediately, but up to 24 h after stress stimulus (interview). Authors of this 
study have suggested that depressed affects could be associated with delayed effects 
in adrenocortical activity in alexithymic subjects and that alexithymic patients who 
responded with elevated depressive symptoms failed to elaborate their emotional 
responses to the consultations (Finset et al., 2006). These findings are in the line with a 
previous study that has found elevated levels of serum cortisol in alexithymic 
individuals (Lindholm et al., 1990). In addition, investigation of the De Timary et al. 
(2008b) performed on 28 healthy male students has shown higher basal stress 
anticipatory saliva cortisol levels in subjects scoring high on alexithymia score (TAS-
20). Multiple regression analyses has shown that the elevated levels of cortisol in high 
alexithymic subjects was due to only one subfactor of alexithymia, ‘‘the difficulty in 
describing feelings’’ factor (DDF) of TAS-20. DDF scores were positively correlated 
only with a large increase in cortisol during anticipation but not during exposure of 
the Trier Social Stress Test (TSST). In this context, De Timary et al. (2008b) reported 
that association of alexithymia with differences in cortisol levels before social stress 
exposure raises the possibility that alexithymia modulates cortisol levels, possibly by 
affecting the anticipatory cognitive appraisal of situations. These findings suggest that 
affect description, likely through activation of prefrontal cortices, decreases amygdala 
activation in response to affective stimuli (Lieberman et al., 2007).  
Close relationship between alexithymia and neuroendocrine changes documents also  
study by Lin et al. (2005) performed on 60 male students that has found significant 
positiv  correlation between total score of TAS-26, including also factor I (DIF) and II 
(DDF), with levels of salivary cortisol.  
There are also some studies that have examined relationship between alexithymia and 
sympathetic adrenal medullary (SAM) system. The first study focused on this topic 
was performed in 17 nondepressed-recovered alcoholic men. The results indicate 
significant positive correlations between alexithymia scores (TAS-26) and SAM/HPA 
ratio (indicated by: urinal 3-methoxy-4-hydroxy-phenyl-ethylene glycol (MHPG)/ 





cortisol level in blood) (Henry et al., 1992). Authors of this study suggested that 
dissociation of the hemispheres appears to be responsible for the alexithymic 
avoidance and failure of the cortisol response that so often follow severe psychological 
trauma (Henry et al., 1992). It was proposed that alexithymia is associated with an 
increased separation of sympatoadrenal and hypothalamo-hypophyseal system and 
that this endocrine hemispheral dissociation has an anatomical basis in lateralization 
of emotions (Henry et al., 1992; Henry 1993, 1997). Similar results documented a study 
by Spitzer et al., (2005) performed on a sample of 12 major depressive disorder (MDD) 
patients and 23 healthy controls. Results of this study indicate that alexithymia is 
associated with an increased noradrenergic activity and a decreased basal activity of 
the HPA axis among men, indicated by decreased levels of urinary cortisol (Spitzer et 
al., 2005).  
Also McCaslin et al. (2006) examined alexithymia (TAS-20), catecholamine response 
(salivary 3-methoxy-4-hydroxy-phenylglycol – major metabolite of norepinephrine 
(MHPG ) and HPA axis response (salivary cortisol) in a sample of 160 police academy 
recruits after exposition to the video stress challenge. Alexithymia scores were 
negatively associated with catecholamine response after the stress stimulus and no 
association was observed between alexithymia scores and salivary cortisol reactivity 
(McCaslin et al 2006). On the other hand, two studies have not confirmed association 
between alexithymia and HPA response (Pedrosa et al., 2007; Guilbaud et al., 2009). 
In addition, there are some findings documenting neuroendocrine changes in 
alexithymia not directly related to major neuroendocrine stress response axes such as 
decreased levels of serum prolactin (Söndergaard and Theorell, 2004) and serum 
oxytocin (Tops et al., 2007) have been found in alexithymic individuals.  
In summary, predominant results of previous research indicate that alexithymia is 
associated with an increased HPA activity (Finset et al., 2006; De Timary et al., 2008; 






































































































































































Several studies suggest that alexithymic features are likely related to disturbances of 
immune functions (Todarello et al., 1997; Guilbaud et al., 2009; Honkalampi et al., 
2011). According to several findings this association is likely directly influenced by 
central nervous system and also mediated by HPA axis, SAM system and autonomic 
nervous system (Martin and Pihl, 1985; Elenkov and Chrousos, 2002; Gündel et al., 
2002).  
Close connection between neuroendocrine and immune systems document also recent 
findings indicating that glucocorticoides and catecholamines present key stress 
hormones produced by HPA and SAM system, that prompt the production of several 
anti-inflammantory cytokines such as IL-4, IL-10 and TGF-β, whereas they inhibit 
production of pro-inflammantory cytokines, such as IL-12, TNF-α (Tumour Necrosis 
Factor Alpha) and INF-γ (Interferon Gamma) (Elenkov and Chrousos, 2002). 
According to the recent evidence, cytokine production may be also directly stimulated 
by stressful experiences and negative emotions (Kiecolt-Glaser et al., 2002) and 
conversely cytokines may be responsible for influence of the HPA and SAM system 
(Zarkovic et al., 2008; Marques et al., 2009; Locatelli et al., 2010). Recent findings 
suggest that interleukine dysregulation presents an important factor responsible for 
chronic impairment of pro/anti-inflammatory cytokine balance due to psychological 
and somatic adversive stimuli that play a significant role in alexithymia (Corcos et al., 
2004). In this context, Guilbaud et al. (2003) suggests that immune dysregulation 
observed in alexithymia, in many aspects seems to follow the same pattern as in 
subjects afflicted with chronic stress with a predominance of depressed cell-mediated 
immunity and a skewed Th1/Th2 ratio towards Th2 response. Together these findings 
suggest that alexithymia likely via mechanisms of both acute and chronic stress likely 
induces dysregulation of immune responses (Elenkov et al., 1996; Marshall et al., 1998; 
Agarwal and Marshall, 2001; Glaser et al., 2001).  
                                 
 
 
                                 1.12.3.2 Alexithymia and leukocytes 
                              
Several studies demonstrated changes of leukocytes counts related to alexithymia. For 
example, study performed by Todarello et al. (1994) in 62 women (36 healthy and 26 
affected by cervical intraepithelial neoplasia - precancerous lesions - CIN I, II, III, who 
were not aware of their condition) found lower rates of almost all lymphocytic subsets 
in alexithymic (SPSS) women in comparison to non-alexithymic. These results were 
successfully replicated by the same author in 1997 performed in bigger sample of 43 
women affected by cervical dysplasia and 67 healthy women with use of TAS-20 





observed between alexithymic women affected by CIN and alexithymic healthy 
women. Women suffering from CIN had higher average TAS-20 ratings than healthy 
women and the alexithymia scores in the group of women suffering from dysplasia 
was higher than that of normal women.  
Another study performed by Dewaraja et al. (1997) on 97 health male subjects also 
reported hypoactivation of cellular immunity (Th1 immune functions) in alexithymic 
subjects (TAS-26). When alexithymia was considered a categorical variable, highly 
alexithymic men had significantly decreased numbers of the most cytotoxic natural 
killer (NK) subset, (CD57-CD16+ cells). Similarly, when alexithymia was considered a 
continuous variable, in addition to the NK subset, killer effector T cell (CD8+CD11a+ 
cells) count was also significantly decreased.  
The both studies by Todarello et al. (1994, 1997) and the study by Dewaraja (1997) are 
in agreement with results reported by other authors (Temoshok, 1987), who 
hypothesized that a certain personality trait characterized by emotional inhibition is 
related to greater cancer vulnerability, and that type of personality might be an 
important factor responsible for the outbreak of cancer. The results of these studies 
proposed that immune system has an important role as a possible mediator between 
personality and cancer and that lowered cytotoxic lymphocytes trigger a mechanism 
that may be responsible for the association between alexithymia and psychosomatic 
illnesses (Dewaraja et al., 1997).  
 
 
                        
1.12.3.3 Alexithymia and cytokines 
 
On the base of previous studies that documented association of alexithymia with 
hypoactivation of cellular immunity further research has contributed to research of 
other characteristics of immune dysregulation related to the alexithymia. In this 
context, study examining cytokines in alexithymia was firstly performed in 17 healthy 
young women by Corcos et al. (2004). Results of this study demonstrated that total 
alexithymia score (TAS-26) is significantly positively correlated with serum levels of 
IL-4 (Corcos et al., 2004). BMI, age, depressed mood and anxiety (HADS) in this study 
were found as independent variables with respect to IL-4 levels and only alexithymia 
likely could have predictive value related to increased levels of IL-4. Serum levels of 
IL-2 and IL-1 were not associated with alexithymia scores in this study. With respect 
to these findings there is evidence that IL-4 together with IL-10 represent major anti-
inflamatory Th2 (type 2) cytokines, which promote humoral immunity and modulate 
key cytokines regulating the type 1/type2 cytokine balance (Elenkov and Chrousos, 
2002). Following these findings Guilbaud et al. (2003) suggested that the 
neuroendocrine and immune response in alexithymic individuals, are similar to 
neuroendocrine and immune patterns in subjects afflicted by chronic stress related to 
up-regulation of Th-2 response and impaired Th-1 response. In this context, increased 





impairment of balance of pro/anti-inflammatory cytokines in alexithymia linked to 
psychological and somatic adverse effects (Corcos et al., 2004). Several researchers also 
emphasize critical importance of the nervous system on maintenance of the balance 
between cell-mediated (Th1) and humoral (Th2) immune responses (Tausk et al., 
2008). For example, Glaser et al. (2001) observed that chronic stressors are associated 
with a dysbalance between Th-1 and Th-2 cytokine response.   
In this context, further studies assesing Th1/Th2-response and its balance were 
performed in alexithymia subjects. For example, investigation by Pedrosa et al. (2007) 
examined 24 subjects with somatoform disorder (SFD) and 9 healthy controls of both 
genders. They found significant relationship of alexithymia (TAS-26) with decreased 
Th1-mediated immune functions indicated by decreased serum levels of IL-2 Rα 
which were negatively correlated with alexithymia [in accordance with previous 
studies the reduction of IL-2Rα levels presents marker of decreased immune 
activation and reduction in Th1-mediated immunity]. The serum levels of IL-4 were 
negatively correlated with the alexithymia, which was incosistent with previous 
findings of Corcos et al. (2004). It has to be noted, however that IL-4 levels were 
detectable only in minority of the examined subjects therefore the results must be 
interpreted whit this important limitation.  
Similarly several other studies have demonstrated altered cell-mediated (Th1) 
immunity in alexithymia. In the study by Guilbaud et al. (2009) performed in 18 
alexithymic and 20 non-alexithymic healthy young women have been found 
significant association between alexithymia (TAS-20) and immune response 
dysbalance between Th1 and Th2 immune response. In this study alexithymia was 
related to decreased production of major type 1 cytokines (IL-2, IL-1β) as well as major 
type 2 cytokine (IL-4), with unchanged levels of the regulatory type 2, represented by 
cytokine IL-10 in vitro production. Cytokine in vitro production remained 
significantly diminished in the alexithymic group, even after adjusting for between-
group differences in anxiety and depression levels on the HADS. Guilbaud et al. 
found reduced ratios of Th1/Th2 (IL-2/IL-10) and CD4/CD8, as well as reduced CD4 
percentages indicating that alexithymic women have altered immune function, with a 
predominance of depressed cell-mediated immunity and a skewed Th1/Th2 ratio 
towards Th2 response. These results confirmed hypothesis of decreased activation of 
Th1 arms, which is consistent with previous data. In contrast to the data published by 
Corcos et al. (2004) simultaneous partial downregulation of Th2 response was found. 
It was also suggested that this contradictory finding could be explained by 
methodological differences applied in this study because cytokines serum levels but 
not cytokine production by stimulated peripheral lymphocytes was meassured. In this 
context Guilbaud et al., proposed that production of IL-4 by other immune cells 
included in previous studies could influence results of the cytokine levels. Together 
the results of this study suggest that alexithymia has specific effect on immunity that 
is probably amplified by anxiety levels and depression. The result of the study also 
suggests that alexithymia could present a vulnerability factor for infectious and stress-





Recent investigation by Mandarelli et al. (2011) in clinical sample of 68 patients (22 
alexithymic, 10 borderline, 36 non-alexithymic), referred for routine upper  
endoscopy, investigated relationship of alexithymia (TAS-20) with stress (SVS), 
depression, anxiety (HADS) and several cytokines (IL-4, IL-6, IFN-γ, IL-1β, TNF-α). 
Alexithymic patients had significantly lower serum levels of IL-4 and IL-6 in 
comparison to non-alexithymic patients. Statistically significant negative correlations 
between alexithymia and IL-4, IL-6 were found. The findings of this study were 
controlled for symptoms of stress, depression, anxiety, BMI, behavioral (smoking, 
coffee drinking, alcohol intake) and sociodemographical (sex, age, marital status, 
education) variables. Multiple regression analysis has confirmed these findings and 
showed that alexithymia is inveresely related to IL-4 as well as IL-6 levels. The 
correlation between other cytokines (IFN-γ, IL-1β, TNF-α) and other 
psychopathological symptoms including alexithymia were not statistically significant. 
The authors suggest that rather than reflecting an isolated shift towards Th2 immune 
response, the results imply that cytokine profiles differs in alexithymic and non-
alexithymic subjects in stresfull conditions, such as endoscopy examination. It is 
summarized that even though the exact meaning of demonstrated cytokine changes 
remains unclear, a possible impairment in the mechanisms underlying immune 
activation might explain the relationship between alexithymia and susceptibility to 
illness (Taylor et al., 1997).  
Another recent study published by Honkalampi et al. (2011) investigated 308 subjects 
from general population and found that TAS-20 score, and all its factors, correlated 
positively with hs-CRP and the BDI scores (Honkalampi et al., 2011). Alexithymic 
subjects had also higher serum levels of IL-6, although this finding did not remain 
significant after in logistic regression analyses adjusted for several counfounders, such 
as depression, and several behavioral and sociodemographical variables. The authors 
suggest that both depression and alexithymia are conditions characterized by a 
pronounced inflammatory state, and could be considered as state reactions to stressful 
situations (Martin and Pihl, 1986). However, the underlying mechanisms for these 
inflammatory changes may differ (Honkalampi et al., 2011).  Similar association of 
serum CRP levels and alexithymia (TAS-20), independently on depression was also 
observed in the study on 145 patients with major depressive disorder (De Berardis et 
al., 2008).   
Supportive evidence of cytokine dysregulation as related to alexithymia reported also  
Temoshok et al. (2008), who performed investigation on 184 HIV-infected subjects and 
found that alexithymic scores (TAS-20) were positively correlated with significantly 
lower stimulated production of HIV-inhibiting MIP-1 alpha (Macrophage 
Inflammatory Protein), which blocks HIV entry into CD4(+) lymphocytes and 
represents key immune parameter implicated in HIV pathogenesis. Increased 
production of MIP-1 alpha and beta which are β-chemokines is associated with more 
favourable status, disease-free HIV patients and protection from infection (Garzino-





significantly higher levels of serum IL-6 presenting a second key immune parameter 
in HIV pathogenesis was also observed.  
Similarly Bossù et al. (2009) has found strong positive correlation between pro-
inflammantory cytokine IL-18 (member of IL-1 family) serum levels and alexithymia 
score (TAS-20) in ischemic stroke patients, particularly in patients with right–
hemisphere lesions. Multivariate analysis indicated specificity of this association. 
Serum IL-18 levels, which is implicated in stroke pathophysilogy and outcome, was 
not significantly corelated with depression severity (HDRS) in this study.  
Also the study by Bruni et al. (2006) reported significant association between 
alexithymia (TAS-20) and serum TNF-α level and between TNF-α level and disease 
activity in 27 rheumatoid arthritis (RA) patients. However this correlation was not 
found in the group of 27 systemic lupus erythematosus (SLE) patients and 27 healthy 
controls. In the similar study by Vadacca et al. (2008) was found increased prevalence 
of alexithymia (TAS-20) in the small groups of SLE (N=12) and RA (N=13) patients. 
Moreover alexithymia was positively associated with increased serum levels of IL-6 
and TNF-α in the proportion of RA patients with high alexithymia in comparison with 
non-alexithymic RA patients.  
Together results of these studies indicate bidirectional interactions between 
alexithymia and immune system in patients affected by autoimmune inflammatory 
diseases. These investigations of autoimmune diseases documented high prevalence 
of alexithymia and a correlation between immunoendocrine parameters and 
alexithymic features in SLE and RA proposing that an immunomodulatory pathway 
could influence this cognitive style in patients with autoimmune disorders. Some 
authors suggested that future research may help to find common biological pathway 
linking alexithymia and autoimmunity (Vadacca et al., 2008). These preliminary 
findings corroborate the integrated bidirectional interactions between 
neuropsychological mechanisms and the neuroendocrine-immune system in patients 
affected by autoimmune diseases and might contribute to explanation of common 
biological pathways linking alexithymia and autoimmune-inflammatory diseases 
(Bruni et al., 2006). 
 




In summary, recent data indicate significant relationships among stress, alexithymia 
and immune dysregulation although there are certain limitations that mainly include 
relatively small sample sizes, heterogeneous patient populations and heterogenous 
methodology of the studies. In the majority of the studies alexithymia was related to 
the reduction in Th1-mediated immune functions (Todarello et al., 1994, 1997; 
Dewaraja et al., 1997; Pedrosa et al., 2007; Guilbaud et al., 2009) and the activation of 





reported studies have not found any significant association between alexithymia and 
impaired immune response (Spivak et al., 1997; Koh et al., 2006). 
In addition, several studies have observed alexithymia related to dysregulation of 
some important inflammatory cytokines that are implicated in innate as well as 
adaptive immunity functions (Corcos et al., 2004; Bruni et al., 2006; Temoshok et al., 





































































































































































































































1.13. CONCLUSIONS BASED ON THE LITERATURE REVIEW 
 
With an attempt to explain basic pathophysiological processes involved in the 
relationship between psychopatological symptoms and somatic health several theories 
have been developed.  Nemiah and Sifneos in 1970s have observed that many patients 
with so-called „psychosomatic diseases” have deficits in capacity of symbolization of 
emotions, verbal behavior, fantasies, and dreams. It was proposed that these 
psychological features can cause numerous symptoms including physiological 
dysfunctions that may result to somatic illnesses. This conceptualisation has evolved 
into the concept of alexithymia that links the influence of emotions and personality on 
physical illness and health.  
In this context, alexithymia could be defined as an inability to complete emotional 
experience, which means, that the person is not able to experience feelings, 
differentiate between various emotional feelings, verbalize  emotional experiences, 
reflect and to some extent analyze  feelings, or fantasize about them (Bermond, 2006).  
Alexithymia is today clinically relevant and multidimensional construct (Kooiman et 
al., 2002; Ogrodniczuk et al., 2011) that reflects general deficit in the cognitive and 
afective processing of emotions (Taylor et al., 1991; Taylor and Bagby, 2004; Bermond 
et al., 2010). Alexithymia is characterised by relative and absolute stability (Tolmunen 
et al., 2011) and is distributed normaly in the general population (Bagby and Taylor, 
1997). Alexithymia consists of both, trait and state components (Tolmunen et al, 2011) 
and the balance between those two components is variable among different subjects 
and situations (Lumley et al., 2007). The prevalence of alexithymia is amounted to be 
around 10-20% (Salminen et al., 1999; Honkalampi et al., 2000a; Quinton and Wagner, 
2005; Moriguchi et al., 2007) in general population, with significatly higher prevalence 
in some clinical samples (Eizaguirre et al., 2004; Parling et al., 2010). Despite of the 
several shortcomings of TAS-20, at present time it remains the most widely used 
instrument for assesing alexithymia (De Gucht et al., 2003).  
Several potential psychosocial, cultural and biological factors are discussed in etiology 
of alexithymia (Taylor and Bagby, 2004). Among most discussed biological 
contributors of alexithymia belong genetic and other neurobiological factors. In this 
context, several recent studies confirmed and strongly supported an important 
contribution of genetic factors to individual differences in alexithymia (Picardi et al., 
2011). According to some authors alexithymic features can be also caused by neural 
dysfunctions, which might result in different emotional-physiological responses 
(Bermond et al., 2006). The prominent fundamental neural structures involved in 
emotional functions, which functional relevance in alexithymia is still discused likely 
include right and left hemisphere, corpus callosum, anterior commissure, anterior 
cingulate, prefrontal cortex, amygdala, and insular cortex (Bermond et al., 2006). In 
spite of the fact that alexithymia was first studied in relationship to the psychosomatic 
illnesses (Taylor et al., 1999), recent research have largely studied and demonstrated 
significant association between alexithymia and various psychopathological states, 





alexithymia has been originally associated with propensity to do poorly in traditional 
dynamic psychotherapy (Sifneos 1973) several recent studies have described positive 
effects of psychotherapy (Grabe et al., 2008b).  
In this context, also some other recent studies have documented that alexithymia is 
related to dysregulation of immune and neuroendocrine functions. Up to date it has 
been published 20 studies examining immune system functions and 10 studies 
examining neuroendocrine response in alexithymia.  Majority of these studies have 
demonstrated increased levels of some inflammatory cytokines, decreased function of 
cellular immunity and hyperactivation of HPA axis in alexithymia. In spite of some 
limitation it could be summarised that stressors related to alexithymia could underlie 
the process of immune and neuroendocrine dysregulation that likely presents a 
significant risk factor in pathogenesis of several medical disorders.   
The previous research has also shown a significant association between alexithymia 
and numerous mental health or physical disorders, including also various pain 
disorders. There are in fact several different pathways potentially acounting for this 
relationship. In an attempt to explain this association several hypotheses were 
proposed. Following recent findings this disertation study is focused on some 
psychoneuroimmunological pathways examining the association between alexithymia 
and immune dysregulation.  
 
 





















2. Empirical Research 
 
 
2.1. CEREBROSPINAL FLUID IL-8 LEVELS REFLECT SYMPTOMS OF 





Several recent findings indicate that various interactions between nervous and 
immune system are important in the pathophysiology of alexithymia (Todarello et al., 
1994, 1997; Dewaraja et al., 1997; Guilbaud et al., 2003, 2009; Corcos et al., 2004; 
Pedrosa et al., 2007). These findings strongly suggest that pro-inflammatory cytokines 
such as IL-1, IL-2, IL- 6, IL-8 and TNF-alpha may play a significant role in developing 
alexithymia and can mediate its psychological and neurobiological manifestations 
(Guilbaud et al., 2003, 2009; Corcos et al., 2004). For example, recent study by Vadacca 
et al. (2008) found increased prevalence of alexithymia (TAS-Toronto Alexithymia 
Scale) in patients with rheumatoid arthritis (RA) (54%) and also in patients with 
systemic lupus erythematosus (SLE) (42%). Both groups of patients had increased 
values of IL-6 and TNF-alpha. Similar study (Bruni et al., 2006) reported association 
between alexithymia (TAS) and increased TNF-alpha levels in RA patients. According 
to recent evidence, cytokine production may be also directly stimulated by negative 
emotions (Kiecolt-Glasser et al., 2002) and conversely cytokines may be responsible for 
influence of the HPA and SAM system (Zarkovic et al., 2008; Marques et al., 2009; 
Locatelli et al., 2010). In this context, recent data also indicate that negative emotions 
related to depressive symptoms and anxiety are related to IL- 8 serum level in patients 
with major depression (Lehto et al., 2010) and anxiety disorder (Hoge et al., 2009). 
These findings suggest that IL-8 could present also useful immunological marker 
related to emotional dysregulation in alexithymia although to this time there is not 
any study that assessed the relationship between symptoms of alexithymia and IL-8. 
IL-8, alternatively known as CXCL8, presents a specific pro-inflammatory cytokine, 
which as a member of the so-called chemokine group with strong chemotaktic 
properties, mainly for neutrophils, but also for other various immunocompetent cells 
(Gerszten et al., 1999; Weik et al., 2008). In addition, several data suggest the role of 
chemokines in cell interaction, neuromodulation, synaptic transmission and 
neuroendocrine functions which represents factors assumed to be important in 
pathophysiology of the various neuropsychic disorders (Lehto et al., 2010; Rostene et 
al., 2010). It has been also documented that IL-8 is related to a variety of  inflammatory 
diseases (Daig  et al., 1996; Kraan et al., 2000), and that  its excessively production can 
lead to damage of  healthy tissue as seen in such disorders as rheumatoid arthritis, 
asthma, periodontitis, irritable bowel disease and cancer. They all show a positive 
association between local as well as systemic levels of IL-8 and severity of diseases 





psychological stress (Herrmann et al., 2000; Bernstein et al., 2006; Weik et al., 2008). 
It is also interesting observation that high levels of circulating IL-8 could induce 
antiinflammatory effect (Kronfol and Remick, 2000; Lehto et al., 2010). Particulary 
interesting and important is the function of chemokines in neurodevelopment and 
synaptic transmission. According to its property as a strong proinflammantory agent 
and its widespread clinical relevance IL-8 seems to be an ideal marker for the 
assessment of psychological effect on the inflammantory respose (Weik et al., 2008). 
This observations could explain why IL-8 would be very interesting in relation to 
alexithymia and anxiety when compare with other proinflammatory cytokines. With 
the purpose to reexamine relationship of IL-8 with depressive and anxiety symptoms, 
and assess the relationship between IL-8 level and alexithymia we have performed 
clinical study of serum and cerebrospinal fluid levels in a group of neurological 
patients with noninflammatory disorders who undergone cerebrospinal fluid 
assessment for diagnostic purposes. In order to specify non-inflammatory conditions 
we have examined serum CRP and also IL-6, immunoglobulines A, G, M and albumin 







                                           
In order to examine the above hypothesis, assessment of IL-8 level in CSF during rest 
conditions and psychometric measures were performed in the selected group of 33 
consecutive inpatients with non-inflammatory neurological disorders (NIND). The 
group patients with NIND were selected from the total group of 210 patients indicated 
for CSF examination. On the base of exclusion criteria we have selected 110 patients 
for psychometric evaluation. From this group only 33 patients have fulfiled inclusion 
criteria and were enroled in this study. The patients were at the time of recruitment 
treated at the Department of Neurology of the University Hospital in Prague. 
Psychometric measures were performed within 8h after lumbar punction and blood 
sample taking. The patients had diagnosis of NIND, which ethiology was related to 
brain small vessel disease or age related ischemic changes on MRI head scans (n = 8), 
axonal neuropathy (n = 7), primary headache (n = 10), cervical or lumbar spondylosis 
(n = 6), and vestibular vertigo (n = 2). The diagnoses were made independently by two 
neurologists of the neurology department. Complete medical history was taken and 
physical, neurological and laboratory examinations were performed to establish 
whether all selected subjects were free of any significant acute or chronic infectious, 
inflammatory or immune disorders, and endocrine abnormalities. CSF examinations 
were indicated in order to exclude autoimune demyelinitative disorder, 
neuroinfection, and other inflammatory states in the context of standard neurological 





blood barrier, assessed by measurement of CSF/serum albumin quotient with age-
dependent reference values. We have also found no evidence of inflammation in 
serum (no increased number of white blood cells and level of C-reactive protein) and 
in the CSF analysis we have not found evidence of pleocytosis, CNS autoimmune 
process with intrathecal immunoglobulin synthesis or oligoclonal bands, monoclonal 
gammopathy and autoantibodies. We have also excluded patients with psychiatric 
diagnosis, drug abuse, current pregnancy, lactation and menstruation in women, and 
also patients with recent history of infectious diseases (influenza or other febril state 
within past 4 weeks). None of the patients had a psychiatric diagnosis according to 
detailed examination by a psychiatrist based on criteria MINI version 5.0.0 (Sheehan 
etal., 1998). All the patients were free of non-steroidal anti-inflammatory medication 
(NSAIDs), methyldopa, corticosteroids and other hormonal medication, and major 
psychotropic drugs for at least 2 months prior to testing. None of the patients had 
received immunomodulatory therapy for 3 months before the lumbar puncture. 
Actually received medication is summarized in Table 3b. The patients were 9 males 
and 24 females in average age 38.78 - 12.48 years (age range 21-60) predominantly 
with high-school education, with adequate nutritional status and body mass index 
(16-29). The study was approved by the university ethical committee and all patients 
gave voluntary written informed consent. Patients were informed about the study 




2.1.2.2. Psychometric meassures 
  
While resting after LP in a patient room of the neurologic department, participants 
completed psychometric questionnaires. Alexithymia was assessed using the 
validated Czech version of the 20-item Toronto Alexithymia Scale (TAS-20) 
(Cronbach’s alpha 0.81, test - retest reliability after1week 0.77) (Bagby et al., 1994a and 
1994b). Each questionis scored on a five - point Likert scale (1 - 5) and the TAS total 
score has range from 20 to 100. Patients were considered to have alexithymia if their 
TAS total score was over 61, whereas patients scoring under 50 were classified as non-
alexithymic. Patients with TAS-20 total score from 51 to 60 were classified as having 
borderline alexithymia (Porcelli et al., 2003). For the assessment of depressive 
symptoms wa sused Czech version of Beck depression inventory BDI-II (Beck et al., 
1996) that represents 21-items questionnaire for assessing depression (Cronbach’s 
alpha 0.89, test - retest reliability after week 0.85). Subjects indicate degree of their 
experience of depressive symptoms on 4-point Likert scale. Levels of anxiety 
symptoms were assessed using the Czech version of The Zung Self-Rating Anxiety 
Scale (SAS) (Cronbach’s alpha 0.89, test – retest reliability after week 0.85) (Zung, 
1971). The SAS is 20-itemself-reporting questionnaire focused on the most common 






2.1.2.3. Lumbar puncture and immunochemical measures 
 
After a night of fasting with bed rest the subjects received standard carbohydrate 
breakfast. The subjects were limited to minimal physical activity and kept quietly 
awake in the neutral environment of the patient room. Usual caffeine intake was 
allowed. For biochemical assessment CSF was drawn from L4-5 or L3-4 interspace 
in upright sitting position between 8 and 9 AM using a standard sterile 
preparation. A total of 8 – 10 ml of CSF was removed and carefully transferred to 
biochemical department and immediately centrifuged and frozen at - 20 C until 
assayed. At the same time, the blood samples of 5 ml volumes were collected into 
sterile tubes according to common procedures and also transferred to the 
biochemical department and immediately centrifuged and frozen at  - 20 C and 
were kept until assayed. The analyses were performed as soon as possible within 
48 hours after serum and CSF sampling. After that serum analyses of CRP and 
also CSF and serum analyses of IL-8, IL-6, immunoglobulines A, G, M and 
albumin have been performed according to common analytical procedures. 
Concentrations of IL-8 in CSF (CSF-IL-8) were measured using double solid-phase 
chemiluminescent enzyme imunnoassay system based on an Immulite/Immulitwe 
1000 (Siemens Medical Solutions Diagnostics). The detection limit for IL-8 was 





2.1.2.4. Statistical methods 
 
Statistical evaluation for results of CSF-IL-8 and other immunochemical measures 
and psychometric measures included means, standard deviations, Mann—
Whitney test for independent samples, Spearman correlation coefficients and 
multiple linear regression analyses. All the methods of statistical evaluation were 





                    
The results indicate that CSF-IL-8 is significantly correlated to TAS-20 (Spearman 
R = 0.46, p = 0.007) and SAS (Spearman R = 0.44, p = 0.009) but not to BDI-II 
(Spearman R = 0.15, p = 0.39) (Table 2b). These correlations show that CSF-IL-8 
exhibits relatively strong relationship to alexithymia, anxiety but not to 
depression. Other statistically significant correlations were also found between 
psychometric measures of alexithymia, anxiety and depression, and alexithymia 





patients (N = 33) were divided into two groups according to values of CSF-IL-8, 
i.e. higher (N1 = 16, IL-8 - 41.90) and lower (N2 = 17; IL-8 < 41.90) than median. 
The results show that statistical comparison using Mann-Whitney test between 
groups of the NIND patients with values of CSF-IL-8 higher and lower than 
median distinguishes the groups of individuals with higher and lower 
alexithymia (TAS-20) (Table 1b). Although the Spearman correlation between 
TAS-20 and CSF-IL-8 is sufficient and it is not necessary to divide the patients in 
to two groups according to values of CSF-IL-8, we used it as a confirmation 
method for correlation analysis. This confirmation is particularly useful because 
Mann - Whitney test usually has higher statistical significance of its results in 
comparison to Spearman correlation coefficient. In addition, using this statistical 
test enables to find whether the results of correlation analysis could be influenced 
by age. In this context, reported data show that the subgroups that are statistically 
significantly different with respect to CSF-IL-8 and TAS-20 are not statistically 
different with respect to age (see Table 1b), which indicate that age likely is not 
responsible for the significant effects observed. Statistical comparison between 
men and women did not show significant differences in CSF-IL-8 or psychometric 
measures. To distinguish the effect of TAS and SAS on CSF-IL-8, we have used a 
multiple linear regression which might be useful, because it is hard to know 
whether alexithymia and anxiety in their specific interactions are linked to 
increased levels of CSF-IL-8 and whether alexithymia and anxiety are tightly 
linked together. The result shows that multiple R = 0.47 is statistically significant 
(p = 0.022; F = 4.297). Other correlations of psychometric measures with serum IL-
8 and CRP, and with serum and CSF levels of IL-6, immunoglobulines A, G, M 
and albumin, were not statistically significant. Also we have not found significant 
correlation between CSF-IL-8 and CSF-IL-6. With exception of the relationship 
between alexithymia and age we have not found any significant association of 
psychometric and immunochemical measures with age and BMI. Also we have 
not found increased CRP in the subgroup with age related ischemic changes as 
well as the one with axonal neuropathy (Figure 1b, Tables 1b, 2b). 
 
 















                                          2.1.4. Tables and figure 
 
 







































 Table 1b. Between group comparison for the NIND patients with higher    









Age 36.87±12.34 40.58±12.71 0.86 0.387 
IL-8 (CSF) 33.55±8.41 48.50±5.51 4.89 <0.0001 
CRP (ser) 1.79±1.32 1.96±1.83 0.15 0.8843 
BDI-II 9.37±10.18 12.70±9.65 1.29 0.1947 
SAS 36.75±8.73 41.88±8.06 1.89 0.0586 
TAS-20 39.12±5.83 49.35±11.94 2.39 0.0166 
 
Note. TAS-20- Toronto Alexithymia Scale; BDI-II- Beck Depression Inventory; SAS- 
Self-reported Anxiety Scale; Higher IL-8 (N1=16, IL-8≥41.90); Lower IL-8 (N2=17; IL-
8<41.90); df=31.  
              
Table 2b. Spearman correlations of CSF-IL-8 with results of psychometric measures. 
 Age IL-8 TAS-20 BDI-II 
Age – – – – 





 – – 











Note. *p < 0.05; **p < 0.01.; TAS-20- Toronto 
Alexithymia Scale; BDI-II- Beck Depression 
Inventory; SAS- Self-reported Anxiety Scale 




































         











Patients Actual medication 
1.-17. No medication 
18.-22. B complex vitamins only 
23. Telmisartan, Hydrochlorothiazide, Omeprazole, Carbamazepine, 
Allopurinol, Tamsulosin  
24. Gabapentin, Fenofibrate  
25.  Piracetam, Metformin, Ramipril, Atorvastatin, B complex 
vitamins, 
26. Betahistine, Rilmenidine, B complex vitamins 
27. Atorvastatin, Tramadol, Betahistine, B complex vitamins 
28.  Carbamazepine 
29. Mefenoxalone, Sulodexide 
30.  Piracetam, Carbamazepine 







                                              2.1.5. Discussion 
 
Results of the present study are in agreement with recent evidence that various 
interactions between nervous and immune system are important in the 
pathophysiology of alexithymia (Todarello et al., 1994; Dewaraja et al., 1997; Todarello 
et al., 1997; Guilbaud et al., 2003, 2009; Corcos et al., 2004; Pedrosa et al., 2007). In this 
context, findings of this study show that heightened level of alexithymia within the 
group of the NIND patients is associated with increased CSF-IL-8. The results also 
show that CSF-IL-8 level significantly increases with heightened occurrence of anxiety 
which is in agreement with findings that patients with anxiety disorder exhibit 
disturbances in IL-8 production (Hoge et al., 2009). In addition we have found that 
alexithymia and anxiety in their specific interaction is linked to increased levels of 
CSF-IL-8 and that alexithymia and anxiety are tightly linked together. Worth of 
mentioning is also result of this study suggesting relationship between alexithymia 
and age which is in agreement with a few reported studies (Pasini et al., 1992; Mattila 
et al., 2006; Moriguchi et al., 2007). The results indicate that IL-8 has relationship to 
alexithymia and anxiety which has not been found in the case of IL-6. The result 
suggests that IL-8 could have exceptional role in mediation of the relationship of 
psychopathological symptoms and inflammantory response. This result is particularly 
interesting although its confirmation needs further research to document whether this 
relationship is specific for IL-8 or whether it may occur also in other cytokines. A 
limitation of the present results is that the group of patients assessed in this study 
appears to be very heterogeneous with regard to their diagnosis and mainly includes 
patients with primary headache and spondolysis. According to clinical experience 
both conditions are painful and it is well known that cytokines and chemokines may 
play a role in inflammatory pain which may implicate that CSF-IL-8 levels in this 
relatively heterogeneous group of patients may reflect also other not clearly 
understood processes related to psychopathological symptoms other than alexithymia 
(Bob, 2008). Other limitation of the present results is that according to the TAS-20 scale 
only 5 of the patients could be likely diagnosed with alexithymia. Nevertheless the 
result may present useful finding within the concept of alexithymia continuum where 
alexithymia is conceptualised preferentially as a dimensional construct, distributed 
normally in the general population (Bagby and Taylor, 1997; De Gucht and Heiser, 
2003). An important explanatory role in this relationship between IL-8 and 
alexithymia could play corticotropin-releasing hormone (CRH) that is closely related 
to locus ceruleus-norepinephrine autonomic neurons of the hypothalamus and 
brainstem and regulate sympathetic nervous activity, and also immune responses 
(Elenkov et al., 2000; Elenkov and Chrousos, 2002). It corresponds to findings of 
several recent studies suggesting dysregulation of the HPA (hypothalamic-pituitary-
adrenal) axis and SAM (sympatho-adreno-medullary reactivity) in alexithymic sub- 
jects (Lindholm et al., 1990; Lin et al., 2005; Finset et al., 2006; De Timary et al., 2008b). 
In addition, IL-8 was identified in different brain areas (e.g. paraventricular nucleus of 





the ACTH [adrenocorticotropic hormone] (Lucinio et al., 1992; Rosténe et al., 2010). 
Important evidence for the research of interactions between neuroimmune 
disturbances in alexithymia present data that IL-8 together with other pro-
inflammatory cytokines IL-1, IL-6, and TNF-alpha present important regulators of 
predominantly innate immunity (Medzhitov et al., 1997; Elenkov, 2008). In this 
context, results of this study present contribution to current findings that also 
cytokines participating in regulation of predominantly innate immunity play an 
important role in pathophysiology of immune dysregulation in alexithymia (Bruni et 
al., 2006; Pedrosa et al., 2007; Vadacca et al., 2008). These findings present a new 
research direction which is complementary to the recent hypothesis that alexithymia is 
related to Th1/Th2 cytokines balance dysregulation reflecting disturbances in adaptive 
immunity (Pedrosa et al., 2007; Guilbaud et al., 2009). Together these findings suggest 
that immune dysregulations related to alexithymia are more complex than was 
previously thought and that genetic predispositions may play a significant role in 
pathogenesis of alexithymia. In this context, future studies focussed on disturbances 
of innate immunity in alexithymia could provide new research directions and 































2.2. ALEXITHYMIA AND NEUROPATHIC PAIN IN SCIATICA 
 
2.1.1. Introduction 
               
Low back pain (LBP) is one of the most frequent health problems (Walker, 2000; 
Strine and Hootman, 2007) and represents one of the most important causes of 
disability, work absenteeism (Van Tulder et al., 1995) and impact on health 
resources (Van Tulder et al., 1995; Awad and Moskovich, 2006). Substantial 
proportion of LBP patients (15%) have sciatica pain, which is considered as a poor 
prognostic indicator associated with more severe pain, disability, time off work 
and worse clinical course (Hill et al., 2011). In addition, there is evidence that 
significant proportion of sciatica patients have neuropathic pain (Baron and 
Binder 2004; Hassan et al., 2004; Freynhagen et al., 2006a and 2006b; Torrance et 
al., 2006; Gustorff et al., 2008; Freynhagen and Baron, 2009; Hill et al., 2011) that is 
associated with higher ratings of pain intensity, co-morbidities such as 
depression, anxiety, sleep disorders and decreased quality of life (Freynhagen et 
al., 2006b). Several psychological factors, including alexithymia are implicated as 
important factors in pathophysiology and management of pain states, however, 
much uncertainty still remains about the weight and functions of these 
psychological factors (Mehling and Krause, 2007).      
According to current studies there is evidence that psychological factors such as 
depressed mood, emotional distress and somatization play a significant role in the 
onset of low back pain (LBP) (Strigo et al, 2010). These factors were also identified 
as risk conditions for transition of the LBP status to chronicity (Pincus et al., 2002; 
Frymoyer, 2010; Linton, 2010; Shaw et al., 2010) and may present an antecedent 
factor predicting development of chronic pain (Fishbain et al., 1997; Shaw et al, 
2010).  
Alhough the association between depression, anxiety and LBP is relativelly well 
known (Freynhagen et al., 2006b) the research concerning relationship between 
alexithymia and LBP is sparse. Indeed, some previous studies have shown that 
alexithymia symptoms predict depression (Kosturek et al., 1998; Lumley et al., 
2002), anxiety (Kosturek et al., 1998), and physical impairment (Lumley et al., 
2002) in patients with various types of chronic pain. Alexithymia also represents 
risk factor for chronic pain, disability, and related health problems (Lumley et al., 
2002). In addition it has been shown that association between alexithymia and 
pain symptoms (persistent pain, acute pain severity and acute pain tolerance) 
presents clinically significant complication in pain patients (Millard and Kinsler, 
1992; Zayfert et al., 1992; Cox et al., 1994; Nyklicek et al., 2000; Lumley et al., 2002; 
Hosoi et al., 2010). In spite of these findings there are however only few 
descriptive or cross-sectional studies that have examined relationship between 
alexithymia and LBP and no study examining alexithymia in sciatica patients. 
Majority of these studies have found  positive relationship between LBP and 





1990; Viikari-Juntura et al., 1991; Mehling et al., 2005) and only one study have 
found negative association between alexithymia and incidence of LBP (Mehling 
and Krause, 2007). In addition, to our knowledge and according to PubMed 
search, there is no study examing relationship between alexithymia and LBP with 
sciatica as well as study examining relationship between alexithymia and 
neuropathic pain in sciatica patients. In this context it is also known that 
alexithymia is related to increased serum levels of C-reactive protein (CRP) (de 
Berardis et al., 2008; Honkalampi et al., 2011) and that increased levels of CRP are 
likely associated with neural lesions in the sciatica pain (Stürmer et al., 2005) and 
may play a role in neuropathic pain generation (Jaggi and Singh, 2011; Noguchi 
and Okubo, 2011; Pabreja et al., 2011; Takahashi et al., 2011). According to our 
knowledge the relationship between CRP and alexithymia in sciatica patients 
have not been reported in recently published studies.  
Moreover several authors suggest that majority of the current findings reported in 
psychological and pain studies of LBP patients are not methodologically 
integrated and most of these investigations included small and heterogeneous 
samples of patients (LaCaille et al. 2005; Edwards et al., 2007) with various pain 
etiology (Carragee, 2001). With respect to the current findings a purpose of this 
study is to examine a hypothesis wheter there is a relationship between 
neuropathic pain and alexithymia. Secondly wheter there is a relationship 
between pain variables (actual pain intensity; maximum pain intensity in last 6 
weeks and average pain intensity also within last 6 weeks) and alexithymia in 
sciatica patients. Further purpose of this study is to examine a hypothesis whether 
there is a relationship between serum CRP levels and alexithymia.  
With the purpose to examine these hypotheses we have investigated a 
homogenous group of sciatica pain patients with intrervertebral disc herniation or 
its combination with spondylotic foraminal stenosis divided into three subgroups 
differentially associated with a level of neuropathic pain component and with 








                                           
In order to examine the above mentioned hypotheses we have performed 
assessment of neuropathic pain, levels of CRP in serum, depressive symptoms, 
anxiety, alexithymia and BMI data in the patients group consisted of 66 
consecutive LBP inpatients suffering from pain related to lower extremity 
involving radicular pain symptoms (sciatica pain). The patients were 28 males and 





high-school education and body mass index (18.90 - 43.50). The study was 
approved by University Ethical Committee and all the patients gave voluntary 
written informed consent. The patient’s had diagnosis of L4, L5 or S1 
radiculopathy caused by intervertebral lumbar disc herniation or its combination 
with spondylotic foraminal stenosis. Complete medical history was taken and 
physical, neurological and laboratory examinations were performed to establish 
whether all selected subjects were free of any inflammatory or oncologic disorders 
that could imitate radiculopathy caused by intervertebral disc herniation. The 
diagnoses were confirmed independently by two neurologists of the neurology 
department. The patients were at the time of recruitment treated at the 
Department of Neurology of the University Hospital in Prague. Exclusion criteria 
included malignant and systemic inflammatory diseases, rheumatoid arthritis, 
ankylosing spondylitis, Reiter’s syndrome, dementia, psychosis and mental 
retardation. Other exclusion criteria were steroid medication, recent history of 




                                         2.2.2.2. Psychometric measures  
                                           
All the participants completed test for neuropathic pain and other psychometric 
measures. Neuropathic pain component was meassured with Czech version of the 
Pain DETECT Questionnaire (PD-Q) (Cronbach's alpha 0.87).  The PD-Q is a reliable 
screening tool used for determination of the prevalence of neuropathic pain 
components in LBP (Freynhagen et al., 2006b). It represents 20-items self-reported 
questionnaire with high sensitivity, specificity and positive predictive accuracy. A 
total score of PD-Q above 18 indicates that a predominantly neuropathic pain 
component is likely, whereas a total score lower than 13 indicates that neuropathic 
pain is unlikely (Freynhagen et al., 2006b).  
Depressive symptoms were assessed using the Czech version of Beck depression 
inventory BDI-II (Beck et al., 1996) that represents 21-items questionnaire for assessing 
depression (Cronbach’s alpha 0.89, test - retest reliability after week 0.85). Subjects 
indicate degree of their experience of depressive symptoms on 4-point Likert scale.  
Levels of anxiety symptoms were assessed using the Czech version of The Zung Self-
Rating Anxiety Scale (SAS) (Cronbach’s alpha 0.89, test – retest reliability after week 
0.85) (Zung, 1971). The SAS is 20-item self-reporting questionnaire focused on the 
most common general anxiety symptoms. Each question is scored on 4-point Likert 
scale from 1 to 4.   
Alexithymia was assessed using the Czech version of the 20-item Toronto Alexithymia 
Scale (TAS-20) (Cronbach’s alpha 0.81, test - retest reliability after 1 week 0.77) (Bagby 
et al., 1994a and 1994b). Each questions scored on a five - point Likert scale (1 - 5) and 






2.2.2.3. Magnetic Resonance Imaging assessment 
 
In order to confirm the clinical diagnosis and for pre-surgical assessment in cases 
indicated for disc surgery intervention we have performed MRI assessment. The 
assessment was focused on lumbar spine using 1.5 Tesla scaner (Magnetom Avanto, 




2.2.2.4. Immunochemical measures of C-reactive protein 
 
Blood samples were taken and immediately transferred for biochemical asessment of 
serum CRP levels that have been performed according to common analytical 
procedures. Concentrations of serum CRP were measured using turbidimetric 
immunoassay method CRP Latex kit (Olympus).  The detection limit for CRP was 0.2 




2.2.2.5. Statistical methods 
 
Statistical evaluation for results of neuropathic pain component, CRP, psychometric 
measures and BMI included means, standard deviations, Spearman correlation 
coefficients, Kruskal-Wallis ANOVA and Mann - Whitney test for independent 
samples. All the methods of statistical evaluation were performed using the software 






Because data did not show presence of significant clusters, the patients (N = 66) were 
divided into three groups according to the presence of neuropathic pain component 
[i.e. neuropathic pain patients N=29, ambiguous group with possible neuropathic pain 
component N=18 and non-neuropathic group N=19]. All the differences (Figure 1c) are 
statistically significant for alexithymia (TAS-20) [at p 0.01, z 4.1], depression (BDI-II) 
[at p 0.01, z 3.9], anxiety (SAS) [at p 0.01, z 4.9], and pain score (PD-Q) [at p 0.015, 
z 2.8]. Also we have found statisticaly significant differences in CRP levels between 
patients with neuropathic and non-neuropathic pain, and between patients with 
neuropathic and ambiguous pain [at p 0.01, z 3.8] (Figure 2c). Other differences were 
not statistically significant. The results show that pain patients with neuropathic pain 






The results also indicate that total score of TAS-20 is significantly correlated to 
depression (BDI) (Spearman R = 0.480, p 0.01), anxiety (SAS) (Spearman R = 0.411, 
p 0.01), but not to pain variables (PD-Q – pain detect score;  Act P – actual pain 
intensity; MP – maximal pain intensity last 6 weeks;  Aver P – average pain intensity 
last 6 weeks) (Table1c). These correlations show that alexithymia exhibits relatively 
strong relationship to depression and anxiety symptoms. Statistical comparison 
between men and women has not shown significant differences in pain or 
psychopathology variables measures.  
To distinguish the effect of acute pain or its chronicity with respect to the neuropathic 
pain component, the psychopathological symptoms and CRP levels, we have divided 
the patients (N= 66) into two subgroups according to sciatica duration. The first group 
consisted of the acute and subacute sciatica patients [N=40; i.e. non-neuropathic 
(N=12); ambiguous (N=11); neuropathic (N=17)] with duration of the pain less than 3 
months. The second group included the chronic sciatica patients [N=26; i.e. non-
neuropathic (N=7); ambiguous (N=7); neuropathic (N=12)] with pain duration more 
than 3 months. Comparison using Mann-Whitney test have found statistically 
significant differences between the subgroups for BDI-II and SAS (p 0.007, Z 2.68) 
indicating that chronic patients have higher level of depression and anxiety (Mean 
BDI-II=15.92; Mean SAS=43.73) than patients with acute pain (Mean BDI-II=10.21; 
Mean SAS=37.16), but we have not found differences for the alexithymia (TAS-20), 
pain score (PD-Q) and other used measures including CRP.  
We have also divided the patients (N=66) into two groups according to the presence of 
motor [N=29; radicular motor weakness or/and deep tendon hyporeflexia] or sensory 
[N=37; radicular pain or/and disturbed sensation in the corresponding dermatomes 
L4-S1] symptoms and found that statistical comparison using Mann-Whitney test did 
not show significant differences between the subgroups. 
 
 
                                                   
























Figure 1c. Scores for the neuropathic, ambiguous and non-neuropathic group. All 
differences are statistically significant for pain score (PD-Q) at p 0.015, z 2.8, 
depression (BDI-II) at p 0.01, z 3.9, anxiety (SAS) at p 0.01, z 4.9, alexithymia (TAS-







































Figure 2c. CRP levels for the neuropathic, non-neuropathic and ambiguous group 
(differences between neuropathic and non-neuropathic pain, and between 

















Table 1c. Spearman correlations of pain variables, psychopathological symptoms, 




 CRP TAS-20 BDI-II SAS PD-Q 
TAS-20 -0,061
 









 – – 
PD-Q 0,051 0,173 0,239 0,368
**
 – 
Act P 0,187 -0,058 0,268 0,248 0,266 
Max P 0,120 -0,047 -0,047 -0,028 0,125 
Aver P 0,132 0,077 0,078 0,043 0,346 
Age -0,080 0,077 -0,032 -0,127 -0,118 
BMI 0,399
**





Note. *p < 0.05; **p < 0.01.; TAS-20- Toronto Alexithymia Scale; BDI-II- Beck Depression 
Inventory; SAS- Self-reported Anxiety Scale; PD-Q – Pain DETECT Questionnaire;  
Act P – actual pain intensity; Max P – maximal pain intensity last 6 weeks;  Aver P – 














Results of this study indicate that increased neuropathic component in sciatica pain is 
associated with elevated levels of alexithymia, depression, anxiety, and serum CRP. 
Based on literature review the results of this study likely present the first finding 
documenting relationship between neuropathic pain and alexithymia in sciatica pain 
patients. These findings are in agreement with the curent data documented in non-
selected LBP patients that has shown significant association between neuropathic pain 
and the higher ratings of pain intensity, depression and anxiety symptoms 
(Freynhagen et al., 2006b). Results of this study suggest significant differences in 
mood factors between nociceptive and neuropathic pain patients.  
In this context, there are several data indicating that some patients with other types of 
“classical” painful neuropathies such as painful polyneuropathies and postherpetic 
neuralgia do not display differences in pain, cognitive and mood symptoms as well as 
in a level of physical suffering with respect to the nociceptive pain patients 
(Haythornthwaite and Benrud-Larson, 2000; Benbow et al., 1998; Galer et al., 2000a, 
2000b).  With respect to these findings, the result of this study suggest that sciatica 
neuropathic pain is associated with different sensory symptoms and different 
mechanisms of neuropathic pain generation in comparson to other painful 
neuropathies (Baron, 2009; Baron et al., 2010).  
Particular importance also has the result indicating significant elevation of serum CRP 
levels in the neuropathic sciatica patients. This observation is in line with recent 
studies strongly suggesting that several inflammatory mediators may potentiate 
neuronal activity and play a role in neuropathic pain generation (Noguchi and Okubo, 
2011; Jaggi and Singh, 2011; Pabreja et al., 2011; Takahashi et al., 2011). These results 
are also in agreement with reported studies indicating that elevated levels of CRP 
could present systemic inflammatory response related to local nerve root 
impingement, which is considered as a main mechanism producing sciatica pain 
(Nygaard et al., 1997; Ahn et al., 2002; Stürmer et al., 2005; Le Gars et al, 2005).  In this 
context, it is known that depression (Miller et al., 2009; Dowlati et al., 2010; 
Honkalampi et al., 2011) as well as alexithymia (de Berardis et al., 2008; Honkalampi 
et al., 2011) are related to increased levels of CRP and therefore the inflammatory-
cytokine pathway might be responsible for the relationship between neuropathic pain 
















Jméno a příjmení........................................................... Rodinný stav................ . Věk ............ 
 
Zaměstnání...................................................................... Vzdělání.................................... ........ 
 
Odpověď  znázorněte na škále od 1 (neodpovídá to mým zkušenostem a pocitům) do 5 (velmi dobře 
odpovídá). 
 
1.  Bývám často zmatený(-á) pokud jde o to, jaké emoce cítím.     1 2 3 4 5 
2. Je pro mne těžké najít správná slova pro mé pocity.   1 2 3 4 5 
3.  Mám fyzické vjemy,  kterým ani lékaři nerozumí.    1 2 3 4 5 
4.  Jsem snadno schopen(-na) popsat mé pocity.    1 2 3 4 5 
5.  Dávám přednost analyzování problémů před jejich popisováním. 1 2 3 4 5 
6.  Když se necítím dobře, nevím jestli jsem smutný(-ná),  
   vyděšený(-ná) nebo rozhněvaný(-ná).     1 2 3 4 5 
7.  Jsem často zmatený(-ná) z pocitů v mém těle.    1 2 3 4 5 
8.  Dávám přednost tomu ponechat věcem volný průběh, před tím 
     než abych se snažil(-a) porozumět tomu proč se takto dějí.  1 2 3 4 5 
9.  Mívám pocity,  které nemohu zcela identifikovat.    1 2 3 4 5 
10. Být ve styku s emocemi je zásadní.    1 2 3 4 5 
11. Zjistil(-a) jsem, že je těžké popsat to, co cítím o lidech.  1 2 3 4 5 
12. Lidé mi říkají, abych více popsal(-a) své pocity.    1 2 3 4 5 
13. Nevím co se ve mně děje.      1 2 3 4 5 
14. Často nevím, proč jsem rozhněvaný(-á).    1 2 3 4 5 
15.  Raději hovořím s lidmi o jejich denních aktivitách  
 spíše než o jejich pocitech.     1 2 3 4 5 
16.  Raději se koukám na „lehký“ zábavný pořad  
 než na psychologické drama.      1 2 3 4 5 
17.  Je pro mne těžké odhalit moje nejvnitřnější city  
 a to i blízkým přátelům.       1 2 3 4 5 
18.  Cítím se blízko někoho i v okamžicích mlčení.    1 2 3 4 5 
19. Zkoumání  mých pocitů považuji za užitečné  
 pro řešení osobních problémů.      1 2 3 4 5 
20. Hledání skrytých významů ve filmech nebo hrách  



























Stupnice hodnocení: 1 – nikdy nebo zřídka, 2 – někdy, 3 – často, 4 – velmi často nebo stále 
 
1. Cítím se více nervózní a úzkostný než je obvyklé.  1 2 3 4 
2. Mám strach a vlastně nevím z čeho.    1 2 3 4 
3. Snadno se rozruším nebo zpanikařím.    1 2 3 4 
4. Mám pocit,že jsem rozvrácený, rozpadlý na kusy.  1 2 3 4 
5. Je se mnou všechno v pořádku a neobávám se ničeho  
nepříjemného                                                                                      1 2 3 4 
6. Cítím chvění a rozklepanost v rukou a nohou.   1 2 3 4 
7. Obtěžují mě bolesti hlavy, bolesti v šíji, bolesti v kříži.  1 2 3 4 
8. Cítím se slabý a snadno se unavím.    1 2 3 4 
9. Jsem klidný a mohu pokojně sedět.    1 2 3 4 
10. Cítím,že srdce mi tluče rychleji.    1 2 3 4 
11. Obtěžují mě závratě.     1 2 3 4 
12. Někdy je mi na omdlení.     1 2 3 4 
13. Volně se mi dýchá.      1 2 3 4 
14. Mám otupělost nebo brnění v prstech na rukou či nohou. 1 2 3 4 
15. Trpím bolestmi žaludku nebo poruchami trávení.  1 2 3 4 
16. Mám časté nutkání močit.     1 2 3 4 
17. Ruce mám obvykle suché a teplé.    1 2 3 4 
18. Mám pocit,že rudnu v obličeji.    1 2 3 4 
19. Snadno usínám a dobře se vyspím.    1 2 3 4 
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AAS - Amsterdam Alexithymia Scale  
                ACC - Anterior Cingulate Cortex 
  Act P - Actual Pain intensity 
ACTH – Adreno-Corticotropic Hormone 
ANS - Autonomic Nervous System  
APRQ - Alexithymia Provoked Response Questionnaire  
Aver P - Average Pain intensity last 6 weeks 
BDI - Beck Depression Inventory 
BIQ - Beth Israel Psychosomatic Questionnaire 
BMI - Body Mass Index 
BVAQ - Bermond-Vorst Alexithymia Questionnaire 
CAQ - California Q-set  
CIN - Cervical Intraepithelial Neoplasia 
CLEM - Conjungate Lateral Eye Movements 
CNS - Central Nervous System 
CRH - Corticotropin-Releasing Hormone 
CRP (hs) - C-Reactive Protein (high-sensitive) 
CSF - Cerebro-Spinal Fluid 
DDF - Difficulty Describing Feelings 
DIF - Difficulty Identifying Feelings  
EEG – Electroencephalography 
EHA - Extrovert-High Alexithymia 
EIS - Kellner´s Emotional Inhibition Scale  
EOT - Externally Oriented Thinking 
ERP - Event Related Potentials  
GHA - General-High Alexithymia  
 HADS - Hospital Anxiety and Depression Scale 
 HDRS - Hamilton Rating Scale for Depression 
HIV - Human Immunodeficiency Virus 
HPA axis - Hypothalamic-Pituitary-Adrenal axis 
Ig - Imunoglobuline 
IHA - Introvert-High Alexithymia  
IL - Interleukine 
INF - Interferon 
KAPP - Karolinska Psychodynamic Profile 
LBP - Low Back Pain 
L-DOPA – L-Dopamin 
LEAS - Levels of Emotional Awareness Scale  





 MDD - Major Depresive Disorder 
MHPG - 3-Methoxy-4-Hydroxy-Phenylglycol  
MIP-1 alpha - Macrophage Inflammatory Protein Alpha 1 
MMPI - Minnesota Multiphasic Personality Inventory 
MP - Maximal Pain  
M-PFC - Medial Prefrontal Cortex 
MRI - Magnetic Resonance Imaging 
N/C ratio - Noepinephrine/Cortisol ratio 
NA - Non-Alexithymia  
NIND - Non-Inflammatory Neurological Disorders  
NK - Natural Killer cell 
NSAID - Non-Steroidal Anti-Inflammatory Drugs 
OAS - Observer Alexithymia Scale  
OCD - Obsessive-Compulsive Disorder  
O-FC – Orbito-Frontal Cortex 
PD-Q - Pain DETECT Questionnaire  
PET – Positron Emision Tomography  
  PFC - Prefrontal Cortex 
                POMS - Profile Of Mood States  
PSE-CATEGO - computer program for the Present State Examination 
PTSD - Postraumatic Stress Disorder 
RA - Rheumatoid Arthritis 
SAM system - Sympatho-Adrenal-Medullary system 
SAS - Zung self-rating Anxiety Scale 
SAT9 - Scored Archetypal Test  
SCL-90 - Symptom Check List-90  
SFD - Somatoform Disorder 
SLE - Systemic Lupus Erythematosus 
 SPSS - Schalling-Sifneos Personality Scale 
 SVS – Stress Vulnerability Scale 
TAS - Toronto Alexithymia Scale 
TAS-20 - Toronto Alexithymia Scale with 20 items 
TAS-26 - Toronto Alexithymia Scale with 26 items 
TAS-R - Revised Toronto Alexithymia Scale with 23 items  
TGF - Tumor Growth Factor 
Th – T helper Lymphocyte 
TNF – Tumor Necrosis Factor 













Alexithymia represents a deficit in identifying and expressing emotions, paucity of 
fantasies, and an externally oriented cognitive style. Currently, numerous studies 
document that alexithymia and several mental and somatic disorders are significantly 
related. Several findings also indicate that this association might be caused by 
alexithymia related dysregulation of neuroendocrine and immune functions. 
Together these findings indicate that stressors related to alexithymia could underlie 
the process of neuroendocrine and immune dysregulation that likely may present a 
significant risk, sustaining and mediating pathogenesis of several disorders and 
particulary psychosomatic illnesses. In this context, it is also known that several 
proinflammatory cytokines may play a role in pain generation and that alexithymia is 
significantly associated with pain symptoms in several pain disorders.  
Following these findings this study includes several new data developing current 
state of the art and showing some alexithymia specific changes in patients with 
neurological disorders. Main finding of this study shows that alexithymia and anxiety 
in their specific interactions are linked to increased levels of interleukine-8 (IL-8) in 
cerebrospinal fluid (CSF) in the group of patients with non-inflammatory 
neurological disorders (NIND). This finding suggests that IL-8 could have 
exceptional role in mediation of the relationship between psychopatological 
symptoms and inflammatory response. 
Other main results of this study indicate that increased neuropathic pain in sciatica 
patients is associated with elevated levels of alexithymia, depression, anxiety and C-
reactive protein (CRP). In this context, several proinflammatory cytokines including 
IL-8 have been suggested to play an important role in pathogenesis of the 
neuropathic pain and may link it to psychopatological symptoms.  
In this context, future studies focused on disturbances of cytokine production in 
alexithymia and other psychopatological symptoms could provide new research 
directions and potentially useful clinical findings in specific groups of neurological 
patients. 
   
 
















Alexithymie představuje poruchu identifikace a vyjadřování emocí a je navíc 
spojena s nedostatkem fantazie a externě orientovaným kognitivním stylem. V 
současnosti je mnoho studií, které popisují významný vztah alexithymie a různých 
psychických a somatických onemocnění. Některé nálezy poukazují na fakt, že tento 
vztah může být zprostředkován narušením neuroendokrinních a imunitních funkcí 
u alexithymických subjektů. Tyto poznatky navíc poukazují na to, že stresové 
podněty u alexithymických subjektů mohou vést k  narušení  neuroendokrinních a 
imunitních funkcí, co může představovat významný rizikový faktor v patogenezi 
různých psychosomatických onemocnění.  V této souvislosti je známo, že pro-
zánětlivé cytokiny mohou hrát významnou roli při vzniku neuropatické bolesti, a že 
alexithymie je dávána do souvislosti se symptomy bolesti u některých poruch.  
Vzhledem k těmto nálezům, tato studie přináší některé nové poznatky o alexithymii 
v případě specifické skupiny neurologických pacientů. Hlavní nález této studie 
ukazuje, že alexithymie a symptomy úzkosti v jejich specifickém vztahu souvisejí se 
zvýšenou hladinou interleukinu-8 (IL-8) v mozkomíšním moku (CSF) a to u skupiny 
pacientů s “nezánětlivými” neurologickými poruchami (NIND). Tyto nálezy také 
naznačují, že IL-8 může hrát výjimečnou roli zprostředkvávající vztah mezi 
psychopatologickými příznaky a procesy zánětu. 
Další důležitý výsledek této studie představuje sledování, že neuropatická bolest u 
pacientů s radikulární bolestí je spojená se zvýšenou úrovní alexithymie, symptomů 
deprese a anxiety a také se zvýšenou hladinou C-reaktívniho proteinu (CRP) v séru. 
Vzhledem k těmto zjištěním jsou různé pro-zánětlivé cytokiny, včetně IL-8, dávány 
do souvislosti s patogenezí neuropatické bolesti a uvažuje se o tom, že můžou 
představovat pojítko mezi neuropatickou bolestí a psychopatologickými symptomy.  
V tomto kontextu, další studie zaměřené na výzkum cytokinů u alexithymie a u 
dalších psychopatologických procesů mohou poskytnout nové výzkumné 
perspektivy a potenciálně užitečné klinické poznatky týkajíci se některých typů 
neurologických onemocnění.  
 
